Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
paper
Cited
Public
Unavailable
- Authors
- Jorenby, Douglas E; Hays, J Taylor; Rigotti, Nancy A; Azoulay, Salomon; Watsky, Eric J; Williams, Kathryn E; Billing, Clare B; Gong, Jason; Reeves, Karen R; Varenicline Phase 3 Study Group
- Year
- 2006
- Journal
- JAMA
- PMID
- 16820547
- DOI
- 10.1001/jama.296.1.56
CONTEXT: Varenicline, a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine. OBJECTIVE: To determine the efficacy and safety of varenicline for smoking cessation compared with placebo or sustained-release bupropion (bupropion SR). DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial conducted between June 2003 and March 2005 at 14 research centers with a 12-week treatment period and follow-up of smoking status to week 52. Of 1413 adult smokers who volunteered for the study, 1027 were enrolled; 65% of randomized participants completed the study. INTERVENTION: Varenicline titrated to 1 mg twice daily (n = 344) or bupropion SR titrated to 150 mg twice daily (n = 342) or placebo (n = 341) for 12 weeks, plus weekly brief smoking cessation counseling. MAIN OUTCOME MEASURES: Continuous abstinence from smoking during the last 4 weeks of treatment (weeks 9-12; primary end point) and through the follow-up period (weeks 9-24 and 9-52). RESULTS: During the last 4 weeks of treatment (weeks 9-12), 43.9% of participants in the varenicline group were continuously abstinent from smoking compared with 17.6% in the placebo group (odds ratio [OR], 3.85; 95% confidence interval [CI], 2.69-5.50; P<.001) and 29.8% in the bupropion SR group (OR, 1.90; 95% CI, 1.38-2.62; P<.001). For weeks 9 through 24, 29.7% of participants in the varenicline group were continuously abstinent compared with 13.2% in the placebo group (OR, 2.83; 95% CI, 1.91-4.19; P<.001) and 20.2% in the bupropion group (OR, 1.69; 95% CI, 1.19-2.42; P = .003). For weeks 9 through 52, 23% of participants in the varenicline group were continuously abstinent compared with 10.3% in the placebo group (OR, 2.66; 95% CI, 1.72-4.11; P<.001) and 14.6% in the bupropion SR group (OR, 1.77; 95% CI, 1.19-2.63; P = .004). Treatment was discontinued due to adverse events by 10.5% of participants in the varenicline group, 12.6% in the bupropion SR group, and 7.3% in the placebo group. The most common adverse event with varenicline was nausea, which occurred in 101 participants (29.4%). CONCLUSIONS: Varenicline is an efficacious, safe, and well-tolerated smoking cessation pharmacotherapy. Varenicline's short-term and long-term efficacy exceeded that of both placebo and bupropion SR. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00143364.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Analysis of Effectiveness of Clinical Psychological Care Protocol for Smoking Cessation With Cytisinicline. | Ramos-Pinedo A et al. | — | 2026 | → |
| An evaluation of cytisinicline for smoking cessation in adult smokers. | Rigotti NA et al. | — | 2026 | → |
| Comparative efficacy in smokers with versus without COPD: a new addition of an old drug to approved pharmacotherapy for smoking cessation. | Tashkin DP et al. | — | 2026 | → |
| GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia. | Bhaduri G et al. | — | 2026 | → |
| Protocol for the Mobile behavioral support plus varenicline for tobacco cessation among people living with HIV in India (MoVIe): A hybrid implementation-effectiveness randomized trial. | Malpeddi T et al. | — | 2026 | → |
| Acetylcholine and Depression: Scrutinizing Future Therapeutic Targets for Novel Drug Development. | Pannu A et al. | — | 2025 | → |
| A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction. | Glenn DL et al. | — | 2025 | → |
| Cytisine for smoking cessation in hospitalised smokers with cardiovascular diseases: an observational study. | Tedesco E et al. | — | 2025 | → |
| Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial. | Rigotti NA et al. | — | 2025 | → |
| Determinants of successful smoking cessation in outpatient settings: A comparative analysis of varenicline and free program interventions. | He Y et al. | — | 2025 | → |
| Dynamic Brain Network Changes Associated with Successful Smoking Cessation | Im JJ et al. | — | 2025 | — |
| EBM BLS: E-Cigarettes and Varenicline are Both Effective for Smoking Cessation. | Qadir N et al. | — | 2025 | → |
| Efficacy of pharmacological intervention for smokeless tobacco cessation in adults: a systematic review and meta-analysis. | Pradhan S et al. | — | 2025 | → |
| Evaluating mediators of the effect of varenicline preloading on smoking abstinence in a randomized controlled trial. | Johnstone S et al. | — | 2025 | → |
| Korean Clinical Practice Guideline of Korean Society for Research on Nicotine and Tobacco (KSRNT) and National Evidence-based Healthcare Collaborating Agency (NECA) on Treatment of Tobacco Use 2024. | Seo YB et al. | — | 2025 | → |
| Longitudinal brain connectivity changes associated with successful smoking cessation. | Im JJ et al. | — | 2025 | → |
| Prize-Based Incentives for Smoking Cessation Among People With HIV: A Sequential Multiple Assignment Randomized Trial. | Ledgerwood DM et al. | — | 2025 | → |
| Smoking cessation in India: A narrative review. | Singh A et al. | — | 2025 | → |
| Smoking Cessation Strategies After Acute Coronary Syndrome. | Nazir A et al. | — | 2025 | → |
| Ten guidelines for a healthy life: Korean Medical Association Statement (2017). | Ahn CM et al. | — | 2025 | → |
| Weaning From Tobacco with Nicotine or Varenicline in Severe and Mild Tobacco Dependence—Findings of a Meta-Analysis. | Selbach C et al. | — | 2025 | → |
| Characterizing reward and relief/habit drinking profiles in a study of naltrexone, varenicline, and placebo. | Kady A et al. | — | 2024 | → |
| Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Outcomes in Heavy Drinkers at 26-Week Follow-up. | Robinson LE et al. | — | 2024 | → |
| Evidence-Based Guideline for the Treatment of Smoking Cessation Provided by the National Health Insurance Service in Korea. | Lee CM et al. | — | 2024 | → |
| Exploring the Link between Altitude of Residence and Smoking Patterns in the United States. | Boxer DJ et al. | — | 2024 | → |
| Identification of Sociodemographic, Clinical, and Genetic Factors to Aid Alaska Native and American Indian People to Successfully Quit Smoking. | Avey JP et al. | — | 2024 | → |
| Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review. | Minian N et al. | — | 2024 | → |
| Insomnia and parasomnia induced by validated smoking cessation pharmacotherapies and electronic cigarettes: a network meta-analysis. | Vanderkam P et al. | — | 2024 | → |
| Seven-membered N-heterocycles as approved drugs and promising leads in medicinal chemistry as well as the metal-free domino access to their scaffolds. | Leśniewska A et al. | — | 2024 | → |
| [Tobacco cessation: one of the most effective medical measures]. | Raspe M et al. | — | 2024 | → |
| Varenicline for E-Cigarette Cessation in Adults: A Preliminary Placebo-Controlled Randomized Trial. | Fucito LM et al. | — | 2024 | → |
| Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial. | Davis JM et al. | — | 2023 | → |
| ADHD symptoms and smoking outcomes in a randomized controlled trial of varenicline for adolescent and young adult tobacco cessation. | Green R et al. | — | 2023 | → |
| Antidepressants for smoking cessation. | Hajizadeh A et al. | — | 2023 | → |
| Challenges and perspectives of tobacco cessation in special groups of patients and populations. | Tsikrika S et al. | — | 2023 | → |
| Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. | Rigotti NA et al. | — | 2023 | → |
| Determining the impact of cannabis use and severity on tobacco cessation outcomes: study protocol for a prospective tobacco treatment trial. | Walters KJ et al. | — | 2023 | → |
| Effectiveness of Bupropion and Varenicline for Smokers With Baseline Depressive Symptoms. | Zhang H et al. | — | 2023 | → |
| Efficacy of Varenicline in the Treatment of Alcohol Dependence: An Updated Meta-Analysis and Meta-Regression. | Phimarn W et al. | — | 2023 | → |
| Efficacy of varenicline versus bupropion for smoking cessation: A systematic review and meta-analysis of randomized controlled trials. | Patel AR et al. | — | 2023 | → |
| First Episode of Psychosis in the Context of Varenicline Treatment for Smoking Cessation. | Zoghbi Y et al. | — | 2023 | → |
| Genomic medicine to reduce tobacco and related disorders: Translation to precision prevention and treatment. | Chen LS et al. | — | 2023 | → |
| Integrative brain structural and molecular analyses of interaction between tobacco use disorder and overweight among male adults. | Zhang M et al. | — | 2023 | → |
| Multiple Pharmacotherapy Adaptations for Smoking Cessation Based on Treatment Response in Black Adults Who Smoke: A Randomized Clinical Trial. | Nollen NL et al. | — | 2023 | → |
| Nicotine receptor partial agonists for smoking cessation. | Livingstone-Banks J et al. | — | 2023 | → |
| Psychopharmacology of smoking cessation medications: focus on patients with mental health disorders. | Castaldelli-Maia JM et al. | — | 2023 | → |
| Pulmonary prehabilitation and smoking cessation. | Ibekwe SO et al. | — | 2023 | → |
| The Usefulness of a Smartphone App-Based Smoking Cessation Program for Conventional Cigarette Users, Heated Tobacco Product Users, and Dual Users: Retrospective Study. | Noda Y et al. | — | 2023 | → |
| Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial. | Caponnetto P et al. | — | 2023 | → |
| Varenicline for smoking cessation in individuals who smoke cigarettes and use electronic cigarettes: a double-blind, randomised, placebo-controlled phase 3 trial. | Caponnetto P et al. | — | 2023 | → |
| Varenicline Treatment for Waterpipe Smoking Cessation. | Chami HA et al. | — | 2023 | → |
| Abrupt versus gradual smoking cessation with pre-cessation varenicline therapy for Chinese treatment-seeking smokers: A retrospective, observational, cohort study. | Zhu N et al. | — | 2022 | → |
| Active versus sham transcranial direct current stimulation (tDCS) as an adjunct to varenicline treatment for smoking cessation: Study protocol for a double-blind single dummy randomized controlled trial. | Zawertailo L et al. | — | 2022 | → |
| Assessing combined effects of varenicline and N-acetylcysteine on reducing nicotine seeking in rats. | Nall RW et al. | — | 2022 | → |
| Deprivation Has Inconsistent Effects on Delay Discounting: A Review. | Downey H et al. | — | 2022 | → |
| Effect of Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Among Smokers Who Drink Heavily: A Randomized Clinical Trial. | King A et al. | — | 2022 | → |
| Effect of Extending the Duration of Prequit Treatment With Varenicline on Smoking Abstinence: A Randomized Clinical Trial. | Hawk LW et al. | — | 2022 | → |
| Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Type 2 Diabetes: A Randomized Clinical Trial. | Russo C et al. | — | 2022 | → |
| Evaluating the effectiveness of bupropion and varenicline for smoking cessation using an internet-based delivery system: A pragmatic randomized controlled trial (MATCH study). | Zhang H et al. | — | 2022 | → |
| Evaluating Treatment Mechanisms of Varenicline: Mediation by Affect and Craving. | Tonkin SS et al. | — | 2022 | → |
| From concepts to treatment: a dialog between a preclinical researcher and a clinician in addiction medicine. | Vandaele Y et al. | — | 2022 | → |
| Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial. | Tønnesen P et al. | — | 2022 | → |
| Optimizing tobacco treatment delivery for people with HIV: trial protocol for a randomized controlled trial. | Sanford BT et al. | — | 2022 | → |
| Protocol from a randomized clinical trial of multiple pharmacotherapy adaptations based on treatment response in African Americans who smoke. | Nollen NL et al. | — | 2022 | → |
| Regulatory Approaches and Implementation of Minimally Addictive Combusted Products. | Hatsukami DK et al. | — | 2022 | → |
| Safety and Effectiveness of Varenicline in Korean Smokers: A Nationwide Post-Marketing Surveillance Study. | Ock M et al. | — | 2022 | → |
| Smoking quit rates among patients receiving pharmacotherapy who received general practitioner counselling versus intensive counselling: a retrospective cohort study. | Yehoshua I et al. | — | 2022 | → |
| The effect of Varenicline and Bupropion on smoking cessation: A network meta-analysis of 20 randomized controlled trials. | Guo K et al. | — | 2022 | → |
| The Effects of Menstrual Cycle Hormones on Responses to Varenicline and Naltrexone Among Female Heavy Drinking Smokers. | Green R et al. | — | 2022 | → |
| Varenicline and related interventions on smoking cessation: A systematic review and network meta-analysis. | Guo K et al. | — | 2022 | → |
| 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors as potential targets for the treatment of nicotine use and dependence. | Higgins GA et al. | — | 2021 | → |
| Abnormal white matter tracts of insula in smokers. | Wang C et al. | — | 2021 | → |
| A double blind randomized controlled trial investigating efficacy and safety of varenicline for smoking cessation in patients with type 2 diabetes: study protocol. | Russo C et al. | — | 2021 | → |
| Attenuating nicotine's effects with high affinity human anti-nicotine monoclonal antibodies. | Raleigh MD et al. | — | 2021 | → |
| Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021. | Nicolau JC et al. | — | 2021 | → |
| Characteristics and Predictors of Abstinence Among Smokers of a Smoking Cessation Clinic in Hunan China. | Hu Y et al. | — | 2021 | → |
| Comparative assessment of outcomes of smoking cessation therapies and role of free medications in successful long-term abstinence. | Saylan B et al. | — | 2021 | → |
| Comparative effects of varenicline or combination nicotine replacement therapy versus patch monotherapy on candidate mediators of early abstinence in a smoking cessation attempt. | Kim N et al. | — | 2021 | → |
| Cue restricted smoking increases quit rates with varenicline. | Scholz JR et al. | — | 2021 | → |
| Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers. | McClure EA et al. | — | 2021 | → |
| Increased striatal functional connectivity is associated with improved smoking cessation outcomes: A preliminary study. | Wang C et al. | — | 2021 | → |
| Interventions for preventing weight gain after smoking cessation. | Hartmann-Boyce J et al. | — | 2021 | → |
| Looking Back and Going Forward: Roles of Varenicline and Electronic Cigarettes in Smoking Cessation. | Oloyede EO et al. | — | 2021 | → |
| New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. | Morley KC et al. | — | 2021 | → |
| Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. | Perez-Paramo YX et al. | — | 2021 | → |
| Population pharmacokinetics and exposure-response analyses of varenicline in adolescent smokers. | Fediuk DJ et al. | — | 2021 | → |
| Providing Free Access to Smoking Cessation Medications: Does It Have an Impact on the Treatment Adherence and Success of Smoking Cessation? | Aksel O et al. | — | 2021 | → |
| Rodent models for nicotine withdrawal. | Chellian R et al. | — | 2021 | → |
| Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. | Thomas KH et al. | — | 2021 | → |
| The impact of three weeks of pre-quit varenicline on reinforcing value and craving for cigarettes in a laboratory choice procedure. | Lawson SC et al. | — | 2021 | → |
| The Persistent Challenge of Developing Addiction Pharmacotherapies. | Swinford-Jackson SE et al. | — | 2021 | → |
| Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. | McRae-Clark AL et al. | — | 2021 | → |
| Varenicline rescues nicotine-induced decrease in motivation for sucrose reinforcement. | Hart E et al. | — | 2021 | → |
| Achieving Smoking Cessation Among Persons with Opioid Use Disorder. | Vlad C et al. | — | 2020 | → |
| An integrated behavioural intervention combined with varenicline for heavy-drinking smokers: a randomized pilot study. | Fucito LM et al. | — | 2020 | → |
| Antidepressants for smoking cessation. | Howes S et al. | — | 2020 | → |
| Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study. | Carney G et al. | — | 2020 | → |
| Co-administration of ethanol and nicotine heightens sensitivity to ethanol reward within the nucleus accumbens (NAc) shell and increasing NAc shell BDNF is sufficient to enhance ethanol reward in naïve Wistar rats. | Waeiss RA et al. | — | 2020 | → |
| Counseling alone or in combination with nicotine replacement therapy for treatment of black non-daily smokers: a randomized trial. | Nollen NL et al. | — | 2020 | → |
| Effect of Early Initiation of Varenicline on Smoking Cessation in COPD Patients Admitted for Exacerbation: The Save Randomized Clinical Trial. | Le Mao R et al. | — | 2020 | → |
| Extending varenicline preloading to 6 weeks facilitates smoking cessation: A single-site, randomised controlled trial. | Bohadana A et al. | — | 2020 | → |
| Factors affecting success and abstinence within a smoking cessation clinic: A one-year follow-up study in Turkey. | Esen AD et al. | — | 2020 | → |
| How health inequalities accumulate and combine to affect treatment value: A distributional cost-effectiveness analysis of smoking cessation interventions. | Love-Koh J et al. | — | 2020 | → |
| Impact of early nausea on varenicline adherence and smoking cessation. | Peng AR et al. | — | 2020 | → |
| Improving translation of animal models of addiction and relapse by reverse translation. | Venniro M et al. | — | 2020 | → |
| Increased thalamic volume and decreased thalamo-precuneus functional connectivity are associated with smoking relapse. | Wang C et al. | — | 2020 | → |
| Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline. | Leone FT et al. | — | 2020 | → |
| Integrated miRNA-/mRNA-Seq of the Habenulo-Interpeduncular Circuit During Acute Nicotine Withdrawal. | Casserly AP et al. | — | 2020 | → |
| Longitudinal effects of smoking cessation on carotid artery atherosclerosis in contemporary smokers: The Wisconsin Smokers Health Study. | Stein JH et al. | — | 2020 | → |
| Modeling drug exposure in rodents using e-cigarettes and other electronic nicotine delivery systems. | Miliano C et al. | — | 2020 | → |
| Nicotine in Senescence and Atherosclerosis. | Centner AM et al. | — | 2020 | → |
| Nomogram to predict successful smoking cessation in a Chinese outpatient population. | Zhu N et al. | — | 2020 | → |
| Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study. | Scoville EA et al. | — | 2020 | → |
| Prolonging the Reduction of Nicotine Self-Administration in Rats by Coadministering Chronic Nicotine With Amitifadine, a Triple Monoamine Reuptake Inhibitor With CYP2B6 Inhibitory Actions. | Levin ED et al. | — | 2020 | → |
| Safety and Efficacy of Varenicline for Smoking Cessation in Alcohol-Dependent Smokers in Concurrent Treatment for Alcohol Use Disorder: A Pilot, Randomized Placebo-Controlled Trial. | Zawertailo L et al. | — | 2020 | → |
| Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing. | Chu S et al. | — | 2020 | → |
| The efficacy and safety of varenicline alone versus in combination with nicotine lozenges for smoking cessation among hospitalised smokers (VANISH): study protocol for a randomised, placebo-controlled trial. | Gobarani RK et al. | — | 2020 | → |
| The Relationship of Varenicline Agonism of α4β2 Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans. | McCaul ME et al. | — | 2020 | → |
| Three metachronous primary lung cancers in a chronic smoker: A case report and review of the literature. | Damania D et al. | — | 2020 | → |
| Varenicline aggravates atherosclerotic plaque formation in nicotine-pretreated ApoE knockout mice due to enhanced oxLDL uptake by macrophages through downregulation of ABCA1 and ABCG1 expression. | Koga M et al. | — | 2020 | → |
| Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations. | Tonstad S et al. | — | 2020 | → |
| Variability in nicotine conditioned place preference and stress-induced reinstatement in mice: Effects of sex, initial chamber preference, and guanfacine. | Lee AM et al. | — | 2020 | → |
| Variation in Patient Smoking Cessation Rates Among Health-Care Providers: An Observational Study. | Almaaitah S et al. | — | 2020 | → |
| Withdrawal Symptom, Treatment Mechanism, and/or Side Effect? Developing an Explicit Measurement Model for Smoking Cessation Research. | Tonkin SS et al. | — | 2020 | → |
| Acute and chronic interactive treatments of serotonin 5HT<sub>2C</sub> and dopamine D<sub>1</sub> receptor systems for decreasing nicotine self-administration in female rats. | Willette BKA et al. | — | 2019 | → |
| Adverse-event management and reporting for electronic cigarettes (e-cigarettes). | Barrett R | — | 2019 | → |
| Assessing nicotine dependence using an oral nicotine free-choice paradigm in mice. | Bagdas D et al. | — | 2019 | → |
| Clinical Efficacy of Telemedicine Compared to Face-to-Face Clinic Visits for Smoking Cessation: Multicenter Open-Label Randomized Controlled Noninferiority Trial. | Nomura A et al. | — | 2019 | → |
| "Cold turkey" or pharmacotherapy: Examination of tobacco cessation methods tried among smokers prior to developing head and neck cancer. | Khariwala SS et al. | — | 2019 | → |
| Differential Posttreatment Outcomes of Methylphenidate for Smoking Cessation for Individuals With ADHD. | Luo SX et al. | — | 2019 | → |
| Efficacy and Safety of Varenicline for Adolescent Smoking Cessation: A Randomized Clinical Trial. | Gray KM et al. | — | 2019 | → |
| Efficacy of smoking cessation with varenicline plus counselling for e-cigarettes users (VAREVAPE): A protocol for a randomized controlled trial. | Caponnetto P et al. | — | 2019 | → |
| Factors That Explain Differences in Abstinence Between Black and White Smokers: A Prospective Intervention Study. | Nollen NL et al. | — | 2019 | → |
| Impact of smoking cessation on clinical outcomes in patients with head and neck squamous cell carcinoma receiving curative chemoradiotherapy: A prospective study. | Chen JL et al. | — | 2019 | → |
| Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. | Glatard A et al. | — | 2019 | → |
| Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking. | Bold KW et al. | — | 2019 | → |
| Modelling continuous abstinence rates over time from clinical trials of pharmacological interventions for smoking cessation. | Jackson SE et al. | — | 2019 | → |
| Nicotine Acts on Cholinergic Signaling Mechanisms to Directly Modulate Choroid Plexus Function. | Lallai V et al. | — | 2019 | → |
| Oral sazetidine-A, a selective α4β2* nicotinic receptor desensitizing agent, reduces nicotine self-administration in rats. | Rezvani AH et al. | — | 2019 | → |
| Prolonged exposure of rats to varenicline increases anxiety and alters serotonergic system, but has no effect on memory. | Zaccarelli-Magalhães J et al. | — | 2019 | → |
| Role of CYP2B6 pharmacogenomics in bupropion-mediated smoking cessation. | Tran AX et al. | — | 2019 | → |
| Schizophrenia and Nicotine Dependence: What Psychopharmacological Treatment Options are Available for the Duo Perturbationes? | Theng YM et al. | — | 2019 | → |
| Short-Term Success Rates of Smoking Cessation Support Programs and Factors Predicting Smoking Relapse: Using Data from a Smoking Cessation Clinic in a Hospital. | Yu SH et al. | — | 2019 | → |
| Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats. | Waeiss RA et al. | — | 2019 | → |
| An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. | Cinciripini PM et al. | — | 2018 | → |
| A randomized clinical trial of counseling and nicotine replacement therapy for treatment of African American non-daily smokers: Design, accrual, and baseline characteristics. | Nollen NL et al. | — | 2018 | → |
| Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation. | Gershon AS et al. | — | 2018 | → |
| Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release. | Hurt RT et al. | — | 2018 | → |
| Cue-induced nicotine-seeking behavior after withdrawal with or without extinction in rats. | Markou A et al. | — | 2018 | → |
| Differential regulation of alcohol taking and seeking by antagonism at α4β2 and α3β4 nAChRs. | Cippitelli A et al. | — | 2018 | → |
| Discovery and development of varenicline for smoking cessation. | Jordan CJ et al. | — | 2018 | → |
| Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers. | Lim AC et al. | — | 2018 | → |
| Effectiveness and safety of varenicline and nicotine replacement therapy among mental health patients: A retrospective cohort study. | Jimenez-Ruiz CA et al. | — | 2018 | → |
| Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. | O'Malley SS et al. | — | 2018 | → |
| Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats. | Maggio SE et al. | — | 2018 | → |
| Effects of varenicline on subjective craving and relative reinforcing value of cigarettes. | Green R et al. | — | 2018 | → |
| Effects of varenicline therapy in combination with advanced behavioral support on smoking cessation and quality of life in inpatients with acute exacerbation of COPD, bronchial asthma, or community-acquired pneumonia: A prospective, open-label, preference-based, 52-week, follow-up trial. | Politis A et al. | — | 2018 | → |
| Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial. | Mercié P et al. | — | 2018 | → |
| Efficacy and Safety of Varenicline for Smoking Cessation in Schizophrenia: A Meta-Analysis. | Ahmed S et al. | — | 2018 | → |
| Estimating the public economic consequences of introducing varenicline smoking cessation therapy in South Korea using a fiscal analytic framework. | Connolly MP et al. | — | 2018 | → |
| Evaluation of Prolonged Exposure to Varenicline in Adult Rats: Haematological, Biochemical and Anatomopathological Studies. | Zaccarelli-Magalhães J et al. | — | 2018 | → |
| Facilitated Extinction Training to Improve Pharmacotherapy for Smoking Cessation: A Pilot Feasibility Trial. | Brandon TH et al. | — | 2018 | → |
| Feasibility and Preliminary Effectiveness of Varenicline for Treating Co-Occurring Cannabis and Tobacco Use. | Adams TR et al. | — | 2018 | → |
| Feasibility of Implementing the All Nations Breath of Life Culturally Tailored Smoking Cessation Program for American Indians in Multi-Tribal Urban Communities. | Daley CM et al. | — | 2018 | → |
| Fiscal Impact of Smoking Cessation in Thailand: A Government Perspective Cost-Benefit Analysis. | Connolly MP et al. | — | 2018 | → |
| Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition. | Denton TT et al. | — | 2018 | → |
| Improvement of Smoking Abstinence Rates With Increased Varenicline Dosage: A Propensity Score-Matched Analysis. | Karam-Hage M et al. | — | 2018 | → |
| Intersection of stress and gender in association with transitions in past year DSM-5 substance use disorder diagnoses in the United States. | Verplaetse TL et al. | — | 2018 | → |
| Linear-rank testing of a non-binary, responder-analysis, efficacy score to evaluate pharmacotherapies for substance use disorders. | Holmes TH et al. | — | 2018 | → |
| MapMySmoke: feasibility of a new quit cigarette smoking mobile phone application using integrated geo-positioning technology, and motivational messaging within a primary care setting. | Schick RS et al. | — | 2018 | → |
| Modulating Neural Circuits with Transcranial Magnetic Stimulation: Implications for Addiction Treatment Development. | Hanlon CA et al. | — | 2018 | → |
| Multimodal treatment for smoking cessation with varenicline in alcoholic, methadone-maintained, and psychotic patients: A one-year follow-up. | Raich A et al. | — | 2018 | → |
| New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. | Bagdas D et al. | — | 2018 | → |
| Nicotine deprivation increases pain intensity, neurogenic inflammation, and mechanical hyperalgesia among daily tobacco smokers. | Ditre JW et al. | — | 2018 | → |
| Pharmacological intervention and abstinence in smokers undergoing cessation treatment: A psychophysiological study. | Cui Y et al. | — | 2018 | → |
| Phase IIb Trial of an α7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence. | Schuster RM et al. | — | 2018 | → |
| Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review. | Stevens ER et al. | — | 2018 | → |
| Scientific Evidence for the Addictiveness of Tobacco and Smoking Cessation in Tobacco Litigation. | Roh S | — | 2018 | → |
| Smoking outcome expectancies predict smoking during voucher-based treatment for smokers with substance use disorders. | Murphy CM et al. | — | 2018 | → |
| Smoking resumption after heart or lung transplantation: a systematic review and suggestions for screening and management. | Hofmann P et al. | — | 2018 | → |
| Sub-anesthetic doses of ketamine attenuate nicotine self-administration in rats. | Rezvani AH et al. | — | 2018 | → |
| The Black Book of Psychotropic Dosing and Monitoring. | Schatzberg AF et al. | — | 2018 | → |
| To Smoke or Not To Smoke: Cigarettes Have a Negative Effect on Wound Healing of Diabetic Foot Ulcers. | Álvaro-Afonso FJ et al. | — | 2018 | → |
| Varenicline and Bupropion for Long-Term Smoking Cessation (the MATCH Study): Protocol for a Real-World, Pragmatic, Randomized Controlled Trial. | Zawertailo L et al. | — | 2018 | → |
| Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial. | Hurt RT et al. | — | 2018 | → |
| Varenicline is a smoking cessation drug that blocks alveolar expansion in mice intratracheally administrated porcine pancreatic elastase. | Koga M et al. | — | 2018 | → |
| Varenicline is associated with a modest limitation in weight gain in smokers after smoking cessation: a meta-analysis. | Sun Y et al. | — | 2018 | → |
| A comparison of the efficacy of varenicline and bupropion and an evaluation of the effect of the medications in the context of the smoking cessation programme. | Benli AR et al. | — | 2017 | → |
| Altered spontaneous activity of posterior cingulate cortex and superior temporal gyrus are associated with a smoking cessation treatment outcome using varenicline revealed by regional homogeneity. | Wang C et al. | — | 2017 | → |
| Altered White Matter Integrity in Smokers Is Associated with Smoking Cessation Outcomes. | Huang P et al. | — | 2017 | → |
| An integrated digital/clinical approach to smoking cessation in lung cancer screening: study protocol for a randomized controlled trial. | Graham AL et al. | — | 2017 | → |
| A Perioperative Smoking Cessation Intervention With Varenicline, Counseling, and Fax Referral to a Telephone Quitline Versus a Brief Intervention: A Randomized Controlled Trial. | Wong J et al. | — | 2017 | → |
| A retrospective analysis of the comparative effectiveness of smoking cessation medication among individuals with mental illness in community-based mental health and addictions treatment settings. | Okoli CTC et al. | — | 2017 | → |
| Combination Varenicline and Lorcaserin for Tobacco Dependence Treatment and Weight Gain Prevention in Overweight and Obese Smokers: A Pilot Study. | Hurt RT et al. | — | 2017 | → |
| Concurrent varenicline and prolonged exposure for patients with nicotine dependence and PTSD: A randomized controlled trial. | Foa EB et al. | — | 2017 | → |
| Effectiveness of intensive practice nurse counselling versus brief general practitioner advice, both combined with varenicline, for smoking cessation: a randomized pragmatic trial in primary care. | van Rossem C et al. | — | 2017 | → |
| Effect of 0.5 mg versus 1 mg varenicline for smoking cessation: a randomized controlled trial. | Fouz-Rosón N et al. | — | 2017 | → |
| Effect of doxazosin on stress reactivity and the ability to resist smoking. | Verplaetse TL et al. | — | 2017 | → |
| Effect of exercise type on smoking cessation: a meta-analysis of randomized controlled trials. | Klinsophon T et al. | — | 2017 | → |
| Effects of ceftriaxone on conditioned nicotine reward in rats. | Philogene-Khalid HL et al. | — | 2017 | → |
| Effects of menthol and its interaction with nicotine-conditioned cue on nicotine-seeking behavior in rats. | Harrison E et al. | — | 2017 | → |
| Efficacy of Varenicline for Cigarette Reduction Before Quitting in Japanese Smokers: A Subpopulation Analysis of the Reduce to Quit Trial. | Nakamura M et al. | — | 2017 | → |
| Emerging pharmacotherapies for alcohol use disorder. | Mason BJ | — | 2017 | → |
| Feasibility and pilot efficacy of a brief smoking cessation intervention delivered by vascular surgeons in the Vascular Physician Offer and Report (VAPOR) Trial. | Goodney PP et al. | — | 2017 | → |
| Guanfacine alters the effect of stress and smoking on heart rate variability in regular daily smokers. | Verplaetse TL et al. | — | 2017 | → |
| Highly Selective and Potent α4β2 nAChR Antagonist Inhibits Nicotine Self-Administration and Reinstatement in Rats. | Wu J et al. | — | 2017 | → |
| Impact of Telephone-Based Care Coordination on Use of Cessation Medications Posthospital Discharge: A Randomized Controlled Trial. | Tague C et al. | — | 2017 | → |
| Increased network centrality as markers of relapse risk in nicotine-dependent individuals treated with varenicline. | Shen Z et al. | — | 2017 | → |
| Longitudinal Impact of Smoking and Smoking Cessation on Inflammatory Markers of Cardiovascular Disease Risk. | King CC et al. | — | 2017 | → |
| Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial. | Shanahan WR et al. | — | 2017 | → |
| Maintenance pharmacotherapy normalizes the relapse curve in recently abstinent tobacco smokers with schizophrenia and bipolar disorder. | Evins AE et al. | — | 2017 | → |
| Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo. | Littlewood RA et al. | — | 2017 | → |
| PET imaging of α<sub>7</sub> nicotinic acetylcholine receptors: a comparative study of [<sup>18</sup>F]ASEM and [<sup>18</sup>F]DBT-10 in nonhuman primates, and further evaluation of [<sup>18</sup>F]ASEM in humans. | Hillmer AT et al. | — | 2017 | → |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | — | 2017 | → |
| Pharmacotherapy in smoking cessation: Corticotropin Releasing Factor receptors as emerging intervention targets. | Sotiriou I et al. | — | 2017 | → |
| Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis. | Smith PH et al. | — | 2017 | → |
| Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment? | Ashare RL et al. | — | 2017 | → |
| Study of monotherapy versus combination therapy for tobacco dependence among heavily addicted smokers. | Ternullo SR et al. | — | 2017 | → |
| Taking varenicline for smoking cessation: A rare cause of pulmonary thromboembolism with infarction. | Lee SH et al. | — | 2017 | → |
| The use of varenicline to treat nicotine dependence among patients with cancer. | Price S et al. | — | 2017 | → |
| The α3β4 nAChR partial agonist AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats. | Yuan M et al. | — | 2017 | → |
| Top 100 Cited Articles in Recent Tobacco Research. | Mahabee-Gittens EM et al. | — | 2017 | → |
| Toward precision smoking cessation treatment II: Proximal effects of smoking cessation intervention components on putative mechanisms of action. | Piper ME et al. | — | 2017 | → |
| Varenicline enhances oxidized LDL uptake by increasing expression of LOX-1 and CD36 scavenger receptors through α<sub>7</sub> nAChR in macrophages. | Kanaoka Y et al. | — | 2017 | → |
| Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo-controlled studies of varenicline. | Tonstad S et al. | — | 2017 | → |
| Varenicline promotes endothelial cell migration by lowering vascular endothelial-cadherin levels via the activated α7 nicotinic acetylcholine receptor-mitogen activated protein kinase axis. | Koga M et al. | — | 2017 | → |
| Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms. | Rohsenow DJ et al. | — | 2017 | → |
| A clinical trial to examine disparities in quitting between African-American and White adult smokers: Design, accrual, and baseline characteristics. | Nollen NL et al. | — | 2016 | → |
| A comparison of neuropsychiatric adverse events during early treatment with varenicline or a nicotine patch. | Cunningham FE et al. | — | 2016 | → |
| Advances in Behavioral Laboratory Methods that Inform Tobacco Regulatory Science: A TCORS Working Group Special Issue. | Wright MJ et al. | — | 2016 | → |
| A key role for the N/OFQ-NOP receptor system in modulating nicotine taking in a model of nicotine and alcohol co-administration. | Cippitelli A et al. | — | 2016 | → |
| Animal Models and the Development of Vaccines to Treat Substance Use Disorders. | Ohia-Nwoko O et al. | — | 2016 | → |
| Are Smoking Cessation Treatments Associated with Suicidality Risk? An Overview. | Penberthy JK et al. | — | 2016 | → |
| Cigarette smoking among Chinese PLWHA: An exploration of changes in smoking after being tested HIV positive. | Wang Y et al. | — | 2016 | → |
| Combination Therapies for Smoking Cessation: A Hierarchical Bayesian Meta-Analysis. | Windle SB et al. | — | 2016 | → |
| Comparative Effectiveness of Smoking Cessation Medications: A National Prospective Cohort From Taiwan. | Chang PY et al. | — | 2016 | → |
| Comparative Effectiveness of Smoking Cessation Medications to Attenuate Weight Gain Following Cessation. | Yang M et al. | — | 2016 | → |
| Continued Smoking in Lung Transplant Patients: A Cross Sectional Survey. | Zmeškal M et al. | — | 2016 | → |
| Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation. | Igarashi A et al. | — | 2016 | → |
| Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse. | Van Skike CE et al. | — | 2016 | → |
| Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers. | Roche DJ et al. | — | 2016 | → |
| Design and initial enrollment in the Vascular Physicians Offer and Report (VAPOR) trial. | Spangler EL et al. | — | 2016 | → |
| Design considerations for a pilot trial using a novel approach for evaluating smoking-cessation medication in methadone-maintained smokers. | Winhusen T et al. | — | 2016 | → |
| Effectiveness of varenicline and counselling for smoking cessation in an observational cohort study in China. | Jiang B et al. | — | 2016 | → |
| Effects of aging on the effectiveness of smoking cessation medication. | Scholz J et al. | — | 2016 | → |
| Effects of Large Financial Incentives for Long-Term Smoking Cessation: A Randomized Trial. | Etter JF et al. | — | 2016 | → |
| Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. | Baker TB et al. | — | 2016 | → |
| Enhancing Quit & Win contests to improve cessation among college smokers: a randomized clinical trial. | Thomas JL et al. | — | 2016 | → |
| Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research. | Czoty PW et al. | — | 2016 | → |
| Exercise to Enhance Smoking Cessation: the Getting Physical on Cigarette Randomized Control Trial. | Prapavessis H et al. | — | 2016 | → |
| Existing and Future Drugs for the Treatment of the Dark Side of Addiction. | Koob GF et al. | — | 2016 | → |
| Factors influencing sustainable efficacy of smoking cessation treatment with varenicline beyond nine months. | Shimadu S et al. | — | 2016 | → |
| Helping patients to reduce tobacco consumption in oncology: a narrative review. | Lucchiari C et al. | — | 2016 | → |
| HIV and smoking: associated risks and prevention strategies. | Kariuki W et al. | — | 2016 | → |
| Integrating tobacco treatment into cancer care: Study protocol for a randomized controlled comparative effectiveness trial. | Park ER et al. | — | 2016 | → |
| In vitro/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl. | Varshosaz J et al. | — | 2016 | → |
| Ligand Binding at the 4-4 Agonist-Binding Site of the 42 nAChR Triggers Receptor Activation through a Pre-Activated Conformational State. | Indurthi DC et al. | — | 2016 | → |
| Nicotine receptor partial agonists for smoking cessation. | Cahill K et al. | — | 2016 | → |
| Nicotinic receptor blockade decreases fos immunoreactivity within orexin/hypocretin-expressing neurons of nicotine-exposed rats. | Simmons SJ et al. | — | 2016 | → |
| Operating on Patients Who Smoke: A Survey of Thoracic Surgeons in the United States. | Marino KA et al. | — | 2016 | → |
| Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio. | Allenby CE et al. | — | 2016 | → |
| Progesterone and Postpartum Smoking Relapse: A Pilot Double-Blind Placebo-Controlled Randomized Trial. | Allen SS et al. | — | 2016 | → |
| Quitting smoking before and after varenicline: a population study based on two representative samples of US smokers. | Zhu SH et al. | — | 2016 | → |
| Reduction of nicotine self-administration by chronic nicotine infusion with H1 histamine blockade in female rats. | Levin ED et al. | — | 2016 | → |
| Safety of Varenicline for Smoking Cessation in Psychiatric and Addicts Patients. | Raich A et al. | — | 2016 | → |
| Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis. | McKee SA et al. | — | 2016 | → |
| Smoking Cessation for People Living With HIV/AIDS: A Literature Review and Synthesis. | Ledgerwood DM et al. | — | 2016 | → |
| Success of a smoking cessation programme in smoking behaviour of chronic periodontitis patients and identification of predictors of motivation for smoking cessation - a pilot study. | Kropff B et al. | — | 2016 | → |
| Targeting the Brain Stress Systems for the Treatment of Tobacco/Nicotine Dependence: Translating Preclinical and Clinical Findings. | Verplaetse TL et al. | — | 2016 | → |
| The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability. | Gueye AB et al. | — | 2016 | → |
| The Effect of Varenicline on the Neural Processing of Fearful Faces and the Subjective Effects of Alcohol in Heavy Drinkers. | Gowin JL et al. | — | 2016 | → |
| The safety of treatments for tobacco use disorder. | Little MA et al. | — | 2016 | → |
| The up-rise in e-cigarette use - friend or foe? | Lundbäck B et al. | — | 2016 | → |
| Time controlled pulsatile transdermal delivery of nicotine: A phase I feasibility trial in male smokers. | Hammann F et al. | — | 2016 | → |
| Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2015. | Szostek JH et al. | — | 2016 | → |
| Use of varenicline for more than 12 months for smoking cessation in heavy chronic obstructive pulmonary disease smokers unmotivated to quit: a pilot study. | Sansores RH et al. | — | 2016 | → |
| Use of Varenicline in Smokeless Tobacco Cessation: A Systematic Review and Meta-Analysis. | Schwartz J et al. | — | 2016 | → |
| Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | Sterling LH et al. | — | 2016 | → |
| Varenicline and Risk of Self-Harm: A Nested Case-Control Study. | Tadrous M et al. | — | 2016 | → |
| Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. | Smith RC et al. | — | 2016 | → |
| Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence. | Burke MV et al. | — | 2016 | → |
| Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. | Eisenberg MJ et al. | — | 2016 | → |
| Varenicline for Smoking Cessation in Light Smokers. | Ebbert JO et al. | — | 2016 | → |
| Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [(11)C]-(+)-PHNO PET Study. | Di Ciano P et al. | — | 2016 | → |
| Abstinence and relapse among smokers who use varenicline in a quit attempt-a pooled analysis of randomized controlled trials. | Agboola SA et al. | — | 2015 | → |
| A combined smoking cessation intervention within a lung cancer screening trial: a pilot observational study. | Pozzi P et al. | — | 2015 | → |
| An exploratory short-term double-blind randomized trial of varenicline versus nicotine patch for smoking cessation in women. | Gray KM et al. | — | 2015 | → |
| An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers. | McClure EA et al. | — | 2015 | → |
| Anxiety, depression, and cigarette smoking: a transdiagnostic vulnerability framework to understanding emotion-smoking comorbidity. | Leventhal AM et al. | — | 2015 | → |
| A randomized controlled trial of the efficacy and safety of varenicline for smoking cessation after acute coronary syndrome: design and methods of the Evaluation of Varenicline in Smoking Cessation for Patients Post-Acute Coronary Syndrome trial. | Windle SB et al. | — | 2015 | → |
| A Review of the Literature Concerning HIV and Cigarette Smoking: Morbidity and Mortality, Associations with Individual- and Social-Level Characteristics, and Smoking Cessation Efforts. | Pacek LR et al. | — | 2015 | → |
| AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology. | Cippitelli A et al. | — | 2015 | → |
| Biologic Approaches to Treat Substance-Use Disorders. | Skolnick P | — | 2015 | → |
| Bupropion-varenicline interactions and nicotine self-administration behavior in rats. | Hall BJ et al. | — | 2015 | → |
| Can electronic cigarettes assist patients with smoking cessation? Yes. | Kaplan A | — | 2015 | → |
| Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. | Kotz D et al. | — | 2015 | → |
| Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. | Chang PH et al. | — | 2015 | → |
| Combining intensive practice nurse counselling or brief general practitioner advice with varenicline for smoking cessation in primary care: study protocol of a pragmatic randomized controlled trial. | van Rossem C et al. | — | 2015 | → |
| Contemporary medical management of peripheral arterial disease: a focus on risk reduction and symptom relief for intermittent claudication. | Agrawal K et al. | — | 2015 | → |
| Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation. | Annemans L et al. | — | 2015 | → |
| CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. | Tomaz PR et al. | — | 2015 | → |
| Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline. | Schassburger RL et al. | — | 2015 | → |
| Effect of oral THC pretreatment on marijuana cue-induced responses in cannabis dependent volunteers. | Lundahl LH et al. | — | 2015 | → |
| Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. | Ebbert JO et al. | — | 2015 | → |
| Empowering smokers with a web-assisted tobacco intervention to use prescription smoking cessation medications: a feasibility trial. | Selby P et al. | — | 2015 | → |
| Evaluating the Effects of Varenicline on Craving, Withdrawal, and Affect in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline for Smokeless Tobacco Dependence in India. | Jhanjee S et al. | — | 2015 | → |
| Examination of the mechanism of action of two pre-quit pharmacotherapies for smoking cessation. | Ferguson SG et al. | — | 2015 | → |
| Extended varenicline treatment in a severe cardiopathic cigarette smoker: a case report. | Munarini E et al. | — | 2015 | → |
| Gender differences in medication use and cigarette smoking cessation: results from the International Tobacco Control Four Country Survey. | Smith PH et al. | — | 2015 | → |
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | Chen LS et al. | — | 2015 | → |
| Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence. | Hancock DB et al. | — | 2015 | → |
| Innovations in translational sex and gender-sensitive tobacco research. | McKee SA et al. | — | 2015 | → |
| Interventions for smokeless tobacco use cessation. | Ebbert JO et al. | — | 2015 | → |
| Neurobiological Bases of Cue- and Nicotine-induced Reinstatement of Nicotine Seeking: Implications for the Development of Smoking Cessation Medications. | Stoker AK et al. | — | 2015 | → |
| New mechanisms and perspectives in nicotine withdrawal. | Jackson KJ et al. | — | 2015 | → |
| Nicotinic receptor contributions to smoking: insights from human studies and animal models. | Brunzell DH et al. | — | 2015 | → |
| Olfactory cue reactivity in nicotine-dependent adult smokers. | Cortese BM et al. | — | 2015 | → |
| Parkinsonism related to varenicline in a patient during smoking cessation. | Uca AU et al. | — | 2015 | → |
| Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers. | Ravva P et al. | — | 2015 | → |
| Pharmacokinetics of cytisine, an α4 β2 nicotinic receptor partial agonist, in healthy smokers following a single dose. | Jeong SH et al. | — | 2015 | → |
| Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers. | Yardley MM et al. | — | 2015 | → |
| Preparation, Optimization, and Screening of the Effect of Processing Variables on Agar Nanospheres Loaded with Bupropion HCl by a D-Optimal Design. | Varshosaz J et al. | — | 2015 | → |
| Reinforcement sensitivity underlying treatment-seeking smokers' affect, smoking reinforcement motives, and affective responses. | Cui Y et al. | — | 2015 | → |
| Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. | Thomas KH et al. | — | 2015 | → |
| Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders. | Fisher ML et al. | — | 2015 | → |
| Role of α4- and α6-containing nicotinic receptors in the acquisition and maintenance of nicotine self-administration. | Madsen HB et al. | — | 2015 | → |
| Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. | Kulik A et al. | — | 2015 | → |
| Smoking and plastic surgery a Montreal perspective. | Matei S et al. | — | 2015 | → |
| Smoking cessation in Asians: focus on varenicline. | Xiao D et al. | — | 2015 | → |
| Smoking cessation-related weight gain--beneficial effects on muscle mass, strength and bone health. | Rom O et al. | — | 2015 | → |
| Smoking cessation strategies in vascular surgery. | Spangler EL et al. | — | 2015 | → |
| Smoking Use and Cessation Among People with Serious Mental Illness. | Annamalai A et al. | — | 2015 | → |
| Social contingencies and college quit and win contest: a qualitative inquiry. | Thomas JL et al. | — | 2015 | → |
| Subunit interfaces contribute differently to activation and allosteric modulation of neuronal nicotinic acetylcholine receptors. | Short CA et al. | — | 2015 | → |
| Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence. | Verplaetse TL et al. | — | 2015 | → |
| The effect of varenicline on the development and expression of nicotine-induced behavioral sensitization and cross-sensitization in rats. | Goutier W et al. | — | 2015 | → |
| The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study. | Froeliger B et al. | — | 2015 | → |
| The fMRI BOLD response to unisensory and multisensory smoking cues in nicotine-dependent adults. | Cortese BM et al. | — | 2015 | → |
| Varenicline and abnormal sleep related events. | Savage RL et al. | — | 2015 | → |
| Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats. | Scuppa G et al. | — | 2015 | → |
| Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial. | de Bejczy A et al. | — | 2015 | → |
| Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. | Ray LA et al. | — | 2015 | → |
| Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats. | Lee AM et al. | — | 2014 | → |
| Antidepressants for smoking cessation. | Hughes JR et al. | — | 2014 | → |
| A pragmatic, randomized, controlled study evaluating the impact of access to smoking cessation pharmacotherapy coverage on the proportion of successful quitters in a Canadian population of smokers motivated to quit (ACCESSATION). | Selby P et al. | — | 2014 | → |
| A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers. | Winhusen TM et al. | — | 2014 | → |
| Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. | Mills EJ et al. | — | 2014 | → |
| Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning. | Gould TJ et al. | — | 2014 | → |
| Clinician's guide to the updated ABCs of cardiovascular disease prevention. | Kohli P et al. | — | 2014 | → |
| Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. | Ebbert JO et al. | — | 2014 | → |
| Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats. | Costello MR et al. | — | 2014 | → |
| Designation of obesity as a disease: lessons learned from alcohol and tobacco. | Hurt RT et al. | — | 2014 | → |
| Effectiveness of pharmacologic therapies on smoking cessation success: three years results of a smoking cessation clinic. | Yilmazel Ucar E et al. | — | 2014 | → |
| Effectiveness of varenicline versus nicotine replacement therapy for smoking cessation with minimal professional support: evidence from an English population study. | Kotz D et al. | — | 2014 | → |
| Effects of chronic varenicline treatment on nicotine, cocaine, and concurrent nicotine+cocaine self-administration. | Mello NK et al. | — | 2014 | → |
| Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. | Hoogsteder PH et al. | — | 2014 | → |
| Emerging drugs for the treatment of tobacco dependence: 2014 update. | Elrashidi MY et al. | — | 2014 | → |
| Enantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective α4β2-nAChR Ligands. | Onajole OK et al. | — | 2014 | → |
| Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation. | Li X et al. | — | 2014 | → |
| Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies. | Simmons SJ et al. | — | 2014 | → |
| Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment. | Cousin MA et al. | — | 2014 | → |
| Nicotinic receptor antagonists as treatments for nicotine abuse. | Crooks PA et al. | — | 2014 | → |
| Organic cation transporter variation and response to smoking cessation therapies. | Bergen AW et al. | — | 2014 | → |
| Oxidative tandem nitrosation/cyclization of N-aryl enamines with nitromethane toward 3-(trifluoromethyl)quinoxalines. | Yang ZJ et al. | — | 2014 | → |
| Perceived medication assignment during a placebo-controlled laboratory study of varenicline: temporal associations of treatment expectancies with smoking-related outcomes. | Correa JB et al. | — | 2014 | → |
| Pharmacotherapy of smoking cessation. | Jiloha RC | — | 2014 | → |
| Phase II crossover trial of varenicline in mild-to-moderate Alzheimer's disease. | Kim SY et al. | — | 2014 | → |
| Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. | Johnson MW et al. | — | 2014 | → |
| Potential role of N-acetylcysteine in the management of substance use disorders. | McClure EA et al. | — | 2014 | → |
| Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokers. | Nakamura M et al. | — | 2014 | → |
| Predictors of smoking lapse in a human laboratory paradigm. | Roche DJ et al. | — | 2014 | → |
| Reinforcing and neural activating effects of norharmane, a non-nicotine tobacco constituent, alone and in combination with nicotine. | Arnold MM et al. | — | 2014 | → |
| Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. | Gonzales D et al. | — | 2014 | → |
| Safety of varenicline tartrate and counseling versus counseling alone for smoking cessation: a randomized controlled trial for inpatients (STOP study). | Carson KV et al. | — | 2014 | → |
| Smoking cessation. | Rennard SI et al. | — | 2014 | → |
| Smoking cessation and the risk of diabetes mellitus and impaired fasting glucose: three-year outcomes after a quit attempt. | Stein JH et al. | — | 2014 | → |
| Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. | Armstrong EJ et al. | — | 2014 | → |
| Smoking, chronic wound healing, and implications for evidence-based practice. | McDaniel JC et al. | — | 2014 | → |
| Smoking habits in the randomised Danish Lung Cancer Screening Trial with low-dose CT: final results after a 5-year screening programme. | Ashraf H et al. | — | 2014 | → |
| Study suggests varenicline safe and effective among adults with stable depression. | Cinciripini PM et al. | — | 2014 | → |
| Substance abuse, memory, and post-traumatic stress disorder. | Tipps ME et al. | — | 2014 | → |
| Synthesis and pharmacological characterization of new neuronal nicotinic acetylcholine receptor ligands derived from Sazetidine-A. | Liu Y et al. | — | 2014 | → |
| Targeting the interaction between fatty acid ethanolamides and nicotinic receptors: therapeutic perspectives. | Melis M et al. | — | 2014 | → |
| The combination of metyrapone and oxazepam for the treatment of cocaine and other drug addictions. | Goeders NE et al. | — | 2014 | → |
| The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors. | Ponzoni L et al. | — | 2014 | → |
| The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada. | von Wartburg M et al. | — | 2014 | → |
| The transplant patient and transplant medicine in family practice. | Hughes LD | — | 2014 | → |
| Tobacco use and cessation for cancer survivors: an overview for clinicians. | Karam-Hage M et al. | — | 2014 | → |
| Tobacco use in the oncology setting: advancing clinical practice and research. | Gritz ER et al. | — | 2014 | → |
| Twelve weeks of smoking cessation therapy with varenicline increases the serum levels of apolipoprotein A-I only in the success group. | Iwaoka M et al. | — | 2014 | → |
| Varenicline aggravates plaque formation through α7 nicotinic acetylcholine receptors in ApoE KO mice. | Koga M et al. | — | 2014 | → |
| Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats. | Igari M et al. | — | 2014 | → |
| Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial. | Nahvi S et al. | — | 2014 | → |
| Varenicline-induced acute dystonic reaction: a case report. | Uca AU et al. | — | 2014 | → |
| Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. | Ray LA et al. | — | 2014 | → |
| Varenicline may reduce negative effect while aiding smoking cessation. | Hays JT | — | 2014 | → |
| 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | Anderson JL et al. | — | 2013 | → |
| 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | Anderson JL et al. | — | 2013 | → |
| A clinician's guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. | Hsu S et al. | — | 2013 | → |
| Adapting smoking cessation treatment according to initial response to precessation nicotine patch. | Rose JE et al. | — | 2013 | → |
| An internet survey of use, opinions and preferences for smoking cessation medications: nicotine, varenicline, and bupropion. | Etter JF et al. | — | 2013 | → |
| Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. | Coffin PO et al. | — | 2013 | → |
| A simple one-pot 2-step <i>N</i>-1-alkylation of indoles with α<i>-</i>iminoketones toward the expeditious 3-step synthesis of <i>N</i>-1-quinoxaline-indoles. | Martinez-Ariza G et al. | — | 2013 | → |
| Brain stimulation methods to treat tobacco addiction. | Wing VC et al. | — | 2013 | → |
| Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. | Grandi SM et al. | — | 2013 | → |
| Cardiovascular effects of pharmacologic therapies for smoking cessation. | Sobieraj DM et al. | — | 2013 | → |
| Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials. | Ware JH et al. | — | 2013 | → |
| Chemistry and pharmacological studies of 3-alkoxy-2,5-disubstituted-pyridinyl compounds as novel selective α4β2 nicotinic acetylcholine receptor ligands that reduce alcohol intake in rats. | Liu Y et al. | — | 2013 | → |
| Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. | Carpenter MJ et al. | — | 2013 | → |
| Commentary on Richmond et al. (2013): Cessation treatment for prisoners. | Hall S | — | 2013 | → |
| Commitment contracts and team incentives: a randomized controlled trial for smoking cessation in Thailand. | White JS et al. | — | 2013 | → |
| Contemporary and optimal medical management of peripheral arterial disease. | Tattersall MC et al. | — | 2013 | → |
| Design, synthesis and discovery of picomolar selective α4β2 nicotinic acetylcholine receptor ligands. | Yenugonda VM et al. | — | 2013 | → |
| Dissociable effect of acute varenicline on tonic versus cue-provoked craving in non-treatment-motivated heavy smokers. | Hitsman B et al. | — | 2013 | → |
| Dopaminergic involvement in effort-based but not impulsive reward processing in smokers. | Freeman TP et al. | — | 2013 | → |
| Down-regulation of amygdala and insula functional circuits by varenicline and nicotine in abstinent cigarette smokers. | Sutherland MT et al. | — | 2013 | → |
| Effectiveness and safety of varenicline as an aid to smoking cessation: results of an inter-Asian observational study in real-world clinical practice. | Wang C et al. | — | 2013 | → |
| Effectiveness of varenicline as an aid to smoking cessation in primary care: an observational study. | Andreas S et al. | — | 2013 | → |
| Effect of varenicline on individual nicotine withdrawal symptoms: a combined analysis of eight randomized, placebo-controlled trials. | Foulds J et al. | — | 2013 | → |
| Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history. | Gould RW et al. | — | 2013 | → |
| Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. | Cinciripini PM et al. | — | 2013 | → |
| Effects of varenicline on abstinence and smoking reward following a programmed lapse. | McClure EA et al. | — | 2013 | → |
| Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. | Anthenelli RM et al. | — | 2013 | → |
| Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. | Hajek P et al. | — | 2013 | → |
| Electrocardiographic changes associated with smoking and smoking cessation: outcomes from a randomized controlled trial. | Gepner AD et al. | — | 2013 | → |
| Extended interactive voice response telephony (IVR) for relapse prevention after smoking cessation using varenicline and IVR: a pilot study. | McNaughton B et al. | — | 2013 | → |
| Fifty-two-week continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy. | Kralikova E et al. | — | 2013 | → |
| Handling relapse in smoking cessation: strategies and recommendations. | Caponnetto P et al. | — | 2013 | → |
| HIV-infected adolescent, young adult and pregnant smokers: important targets for effective tobacco control programs. | Escota G et al. | — | 2013 | → |
| How can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use? | McKee SA et al. | — | 2013 | → |
| Individual differences in amygdala reactivity following nicotinic receptor stimulation in abstinent smokers. | Sutherland MT et al. | — | 2013 | → |
| Interoceptive conditioning with a nicotine stimulus is susceptible to reinforcer devaluation. | Pittenger ST et al. | — | 2013 | → |
| Interventions for tobacco smoking. | Schlam TR et al. | — | 2013 | → |
| Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. | Hajek P et al. | — | 2013 | → |
| Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness. | Nahvi S et al. | — | 2013 | → |
| Managing tobacco use: the neglected cardiovascular disease risk factor. | Rigotti NA et al. | — | 2013 | → |
| Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice. | Quik M et al. | — | 2013 | → |
| Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. | Hendrickson LM et al. | — | 2013 | → |
| Neuropsychiatric adverse events of varenicline: a systematic review of published reports. | Ahmed AI et al. | — | 2013 | → |
| Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease. | Quik M et al. | — | 2013 | → |
| Novel nicotinic acetylcholine receptor agonists containing carbonyl moiety as a hydrogen bond acceptor. | Mazurov AA et al. | — | 2013 | → |
| Ongoing self-engagement in quit attempts and cessation outcomes among rural smokers who were unable to quit after 2 years of repeated interventions. | Hui SK et al. | — | 2013 | → |
| Pharmacological interventions for smoking cessation: an overview and network meta-analysis. | Cahill K et al. | — | 2013 | → |
| Pharmacological properties and predicted binding mode of arylmethylene quinuclidine-like derivatives at the α3β4 nicotinic acetylcholine receptor (nAChR). | Kombo DC et al. | — | 2013 | → |
| Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration. | Liu X | — | 2013 | → |
| Smoking cessation and COPD. | Tønnesen P | — | 2013 | → |
| Smoking cessation in patients with respiratory disease: existing treatments and future directions. | Rigotti NA | — | 2013 | → |
| [Smoking cessation therapy in thoracic oncology]. | Ruppert AM et al. | — | 2013 | → |
| Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions. | Getsios D et al. | — | 2013 | → |
| The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. | Louie S et al. | — | 2013 | → |
| The effectiveness of varenicline medication guide for conveying safety information to patients: a REMS assessment survey. | Enger C et al. | — | 2013 | → |
| Therapeutic vaccines against tobacco addiction. | Fahim RE et al. | — | 2013 | → |
| The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence. | Muldoon PP et al. | — | 2013 | → |
| Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction? | Nocente R et al. | — | 2013 | → |
| Varenicline induced acute interstitial nephritis in the setting of idiopathic membranous glomerulonephritis. | Kwong W et al. | — | 2013 | → |
| Varenicline-induced coronary thrombosis. | Kalayci A et al. | — | 2013 | → |
| Varenicline to stop long-term nicotine replacement use: a double-blind, randomized, placebo-controlled trial. | Tønnesen P et al. | — | 2013 | → |
| 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. | Rooke TW et al. | — | 2012 | → |
| 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. | Fihn SD et al. | — | 2012 | → |
| 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. | Fihn SD et al. | — | 2012 | → |
| Acute baclofen diminishes resting baseline blood flow to limbic structures: a perfusion fMRI study. | Franklin TR et al. | — | 2012 | → |
| Adherence to varenicline and abstinence rates for quitting smoking in a private health promotion center-based smoking cessation clinic. | Lee JY et al. | — | 2012 | → |
| Adverse neuropsychiatric events associated with varenicline use in veterans: a case series. | Cantrell M et al. | — | 2012 | → |
| A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. | Rennard S et al. | — | 2012 | → |
| A Review of Smoking Cessation in Bipolar Disorder: Implications for Future Research. | George TP et al. | — | 2012 | → |
| Assessing preferences for improved smoking cessation medications: a discrete choice experiment. | Marti J | — | 2012 | → |
| Assessing the effects of chronic sazetidine-A delivery on nicotine self-administration in both male and female rats. | Johnson JE et al. | — | 2012 | → |
| Atomoxetine treatment for nicotine withdrawal: a pilot double-blind, placebo-controlled, fixed-dose study in adult smokers. | Silverstone PH et al. | — | 2012 | → |
| Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. | Tiffany ST et al. | — | 2012 | → |
| Changes in health-related quality of life with smoking cessation treatment. | Hays JT et al. | — | 2012 | → |
| Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain. | Hussmann GP et al. | — | 2012 | → |
| Cigarette smoking and chronic kidney diseases. | Nagasawa Y et al. | — | 2012 | → |
| Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. | Mills EJ et al. | — | 2012 | → |
| Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece. | Athanasakis K et al. | — | 2012 | → |
| Developing and validating a human laboratory model to screen medications for smoking cessation. | McKee SA et al. | — | 2012 | → |
| Developing a Rational Approach to Tobacco Use Treatment in Pulmonary Practice: A Review of the Biological Basis of Nicotine Addiction. | Leone FT et al. | — | 2012 | → |
| Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. | Mazurov AA et al. | — | 2012 | → |
| Effectiveness of varenicline for smoking cessation at 2 urban academic health centers. | Dhelaria RK et al. | — | 2012 | → |
| Effects of the combination of metyrapone and oxazepam on intravenous nicotine self-administration in rats. | Goeders NE et al. | — | 2012 | → |
| Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers. | Ashare RL et al. | — | 2012 | → |
| Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. | Tønnesen P et al. | — | 2012 | → |
| How do perceptions about cessation outcomes moderate the effectiveness of a gain-framed smoking cessation telephone counseling intervention? | Latimer-Cheung AE et al. | — | 2012 | → |
| Impact of varenicline on cue-specific craving assessed in the natural environment among treatment-seeking smokers. | Gass JC et al. | — | 2012 | → |
| Interventions for preventing weight gain after smoking cessation. | Farley AC et al. | — | 2012 | → |
| Long-term effects of smoking and smoking cessation on exercise stress testing: three-year outcomes from a randomized clinical trial. | Asthana A et al. | — | 2012 | → |
| Medical therapy for peripheral arterial disease. | Simmons A et al. | — | 2012 | → |
| Nicotine receptor partial agonists for smoking cessation. | Cahill K et al. | — | 2012 | → |
| Pharmacologic agents for tobacco dependence treatment: 2011 update. | Hays JT et al. | — | 2012 | → |
| Plasma levels of metabolites of catecholamine in nicotine-dependent patients treated with varenicline. | Umene-Nakano W et al. | — | 2012 | → |
| Preventive aspects in peripheral artery disease. | Aggarwal S et al. | — | 2012 | → |
| Prisoners and cigarettes or 'imprisoned in cigarettes'? What helps prisoners quit smoking? | Makris E et al. | — | 2012 | → |
| Rational development of addiction pharmacotherapies: successes, failures, and prospects. | Pierce RC et al. | — | 2012 | → |
| Receptor and channel heteromers as pain targets. | Berg KA et al. | — | 2012 | → |
| RegIIA: an α4/7-conotoxin from the venom of Conus regius that potently blocks α3β4 nAChRs. | Franco A et al. | — | 2012 | → |
| Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. | Prochaska JJ et al. | — | 2012 | → |
| RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. | Huang YZ et al. | — | 2012 | → |
| S-adenosyl-L-methionine (SAMe) for smoking abstinence: a randomized clinical trial. | Sood A et al. | — | 2012 | → |
| Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study. | Cui Q et al. | — | 2012 | → |
| Smoking and HIV: prevalence, health risks, and cessation strategies. | Lifson AR et al. | — | 2012 | → |
| Smoking cessation after brain damage does not lead to increased depression: implications for understanding the psychiatric complications of varenicline. | Tranel D et al. | — | 2012 | → |
| Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. | King DP et al. | — | 2012 | → |
| Smoking cessation: present status and future perspectives. | Caponnetto P et al. | — | 2012 | → |
| Smoking cessation therapy during pregnancy. | Cressman AM et al. | — | 2012 | → |
| Strategies to help a smoker who is struggling to quit. | Rigotti NA | — | 2012 | → |
| Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation. | Mahmoudi M et al. | — | 2012 | → |
| The clinical significance of drug craving. | Tiffany ST et al. | — | 2012 | → |
| The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial. | Hawk LW et al. | — | 2012 | → |
| The effects of varenicline on attention and inhibitory control among treatment-seeking smokers. | Rhodes JD et al. | — | 2012 | → |
| The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial. | Hoogsteder PH et al. | — | 2012 | → |
| The Fagerström Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. | Fagerström K et al. | — | 2012 | → |
| The impact of the Georgia Health Sciences University nursing faculty practice on tobacco cessation rates. | Heath J et al. | — | 2012 | → |
| The nicotinic acetylcholine receptor as a target for antidepressant drug development. | Philip NS et al. | — | 2012 | → |
| Use of the Patient Health Questionnaire-2 to predict suicidal ideations in patients taking varenicline. | Cowan CM et al. | — | 2012 | → |
| Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study. | Gratziou C et al. | — | 2012 | → |
| Varenicline decreases alcohol consumption in heavy-drinking smokers. | Mitchell JM et al. | — | 2012 | → |
| Varenicline dose dependently enhances responding for nonpharmacological reinforcers and attenuates the reinforcement-enhancing effects of nicotine. | Levin ME et al. | — | 2012 | → |
| Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial. | Pachas GN et al. | — | 2012 | → |
| Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum. | Bordia T et al. | — | 2012 | → |
| Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial. | Gray KM et al. | — | 2012 | → |
| Weight gain in smokers after quitting cigarettes: meta-analysis. | Aubin HJ et al. | — | 2012 | → |
| 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | Anderson JL et al. | — | 2011 | → |
| 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. | Wright RS et al. | — | 2011 | → |
| 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline). | American College of Cardiology Foundation et al. | — | 2011 | → |
| 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. | 2011 WRITING GROUP MEMBERS et al. | — | 2011 | → |
| 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | Rooke TW et al. | — | 2011 | → |
| 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. | Rooke TW et al. | — | 2011 | → |
| 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | Hillis LD et al. | — | 2011 | → |
| 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. | Hillis LD et al. | — | 2011 | → |
| Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies. | Steinberg MB et al. | — | 2011 | → |
| [Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care]. | Sicras Mainar A et al. | — | 2011 | → |
| A comparison of brain and behavioral effects of varenicline and nicotine in rats. | King J et al. | — | 2011 | → |
| Activation of the opioid μ1, but not δ or κ, receptors is required for nicotine reinforcement in a rat model of drug self-administration. | Liu X et al. | — | 2011 | → |
| Addiction and brain reward and antireward pathways. | Gardner EL | — | 2011 | → |
| Adherence to varenicline in the COMPASS smoking cessation intervention trial. | Catz SL et al. | — | 2011 | → |
| A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data. | Xenakis JG et al. | — | 2011 | → |
| A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females. | Evins AE et al. | — | 2011 | → |
| A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. | Garza D et al. | — | 2011 | → |
| A manic episode in a 64-year-old man: an adverse effect of varenicline. | Ahmed AI | — | 2011 | → |
| A novel recruitment message to increase enrollment into a smoking cessation treatment program: preliminary results from a randomized trial. | Schnoll RA et al. | — | 2011 | → |
| Anterior cingulate proton spectroscopy glutamate levels differ as a function of smoking cessation outcome. | Mashhoon Y et al. | — | 2011 | → |
| A pilot clinical trial of varenicline for smoking cessation in black smokers. | Nollen NL et al. | — | 2011 | → |
| A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States. | Ebbert JO et al. | — | 2011 | → |
| Approach to smoking cessation in the patient with vascular disease. | Ratchford EV et al. | — | 2011 | → |
| A preliminary investigation of varenicline for heavy drinking smokers. | Fucito LM et al. | — | 2011 | → |
| A review of tobacco use treatments in U.S. ethnic minority populations. | Cox LS et al. | — | 2011 | → |
| A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia. | Yousefi MK et al. | — | 2011 | → |
| Australia's experience with varenicline: usage, costs and adverse reactions. | Walsh RA | — | 2011 | → |
| Biomarkers to optimize the treatment of nicotine dependence. | Schnoll RA et al. | — | 2011 | → |
| Contingency management for behavior change: applications to promote brief smoking cessation among opioid-maintained patients. | Dunn KE et al. | — | 2011 | → |
| Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation. | Javitz HS et al. | — | 2011 | → |
| Current challenges for the creation of effective vaccines against drugs of abuse. | Moreno AY et al. | — | 2011 | → |
| Differences in Substance Abuse Counselors' Knowledge of Tobacco Cessation Medication Effectiveness: 2002-2008. | Rothrauff TC et al. | — | 2011 | → |
| Dopamine transporter genotype modulation of neural responses to smoking cues: confirmation in a new cohort. | Franklin TR et al. | — | 2011 | → |
| Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study. | Boudrez H et al. | — | 2011 | → |
| Effectiveness of varenicline for smoking cessation: a 1-year follow-up study. | Grassi MC et al. | — | 2011 | → |
| Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims. | Zeng F et al. | — | 2011 | → |
| Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. | Gepner AD et al. | — | 2011 | → |
| Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. | Bolliger CT et al. | — | 2011 | → |
| Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. | Tashkin DP et al. | — | 2011 | → |
| Efficacy of a flexible quit date versus an a priori quit date approach to smoking cessation: a cross-study analysis. | Hughes JR et al. | — | 2011 | → |
| Electron impact mass spectral study of halogenated N-acetyl- and N-propionylcytisines. | Przybył AK et al. | — | 2011 | → |
| Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis. | Leung LK et al. | — | 2011 | → |
| How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey. | Le Strat Y et al. | — | 2011 | → |
| Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. | Vemer P et al. | — | 2011 | → |
| Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients. | Tashkin DP et al. | — | 2011 | → |
| Management of Crohn's disease in smokers: is an alternative approach necessary? | Nos P et al. | — | 2011 | → |
| Mechanistic insights into nicotine withdrawal. | Paolini M et al. | — | 2011 | → |
| New methods for tobacco dependence treatment research. | Baker TB et al. | — | 2011 | → |
| Nicotine receptor partial agonists for smoking cessation. | Cahill K et al. | — | 2011 | → |
| Nicotinic acetylcholine receptors containing the α4 subunit are critical for the nicotine-induced reduction of acute voluntary ethanol consumption. | Hendrickson LM et al. | — | 2011 | → |
| Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. | Huang LZ et al. | — | 2011 | → |
| Observational study of safety and efficacy of varenicline for smoking cessation among Filipino smokers. | Park PW et al. | — | 2011 | → |
| Pharmacotherapeutic management of nicotine dependence in pregnancy. | Clark SM et al. | — | 2011 | → |
| [Pharmacotherapies for nicotine dependence: review of scientific evidence. Spanish Society of Smoking Specialists: recommendations about election and individualization]. | Olano Espinosa E et al. | — | 2011 | → |
| Pharmacotherapy for smoking. | Allan GM et al. | — | 2011 | → |
| Photoelectric stimulation of defined ear points (Smokex-Pro method) as an aid for smoking cessation: a prospective observational 2-year study with 156 smokers in a primary care setting. | Breivogel B et al. | — | 2011 | → |
| Predictors of smoking cessation among cancer patients enrolled in a smoking cessation program. | Schnoll RA et al. | — | 2011 | → |
| Preventing lung cancer by treating tobacco dependence. | Hurt RD et al. | — | 2011 | → |
| Racial differences in eligibility and enrollment in a smoking cessation clinical trial. | King AC et al. | — | 2011 | → |
| Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. | Xie P et al. | — | 2011 | → |
| Recent advances in gene manipulation and nicotinic acetylcholine receptor biology. | Tammimäki A et al. | — | 2011 | → |
| Repeated administration of the GABAB receptor positive modulator BHF177 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine seeking in rats. | Vlachou S et al. | — | 2011 | → |
| Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. | Singh S et al. | — | 2011 | → |
| Selective α4β2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neurons. | Maloku E et al. | — | 2011 | → |
| Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers. | Kikkawa H et al. | — | 2011 | → |
| Smoking cessation treatment among patients in community-based substance abuse rehabilitation programs: exploring predictors of outcome as clues toward treatment improvement. | Reid MS et al. | — | 2011 | → |
| Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned? | Gibbons RD et al. | — | 2011 | → |
| Structure-activity studies of diazabicyclo[3.3.0]octane-substituted pyrazines and pyridines as potent α4β2 nicotinic acetylcholine receptor ligands. | Scanio MJ et al. | — | 2011 | → |
| The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations. | Heffner JL et al. | — | 2011 | → |
| The effects of nicotine and cigarette smoke on the monoamine transporters. | Danielson K et al. | — | 2011 | → |
| The multiphase optimization strategy for engineering effective tobacco use interventions. | Collins LM et al. | — | 2011 | → |
| The role of pharmacotherapy in mild to moderate chronic obstructive pulmonary disease. | Raghavan N et al. | — | 2011 | → |
| The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice. | Wildeboer-Andrud KM et al. | — | 2011 | → |
| Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. | Steinberg MB et al. | — | 2011 | → |
| Tobacco smoking and mental illness: important considerations. | Feeney S et al. | — | 2011 | → |
| Translational research in addiction: toward a framework for the development of novel therapeutics. | Paterson NE | — | 2011 | → |
| Treatment of nicotine addiction: present therapeutic options and pipeline developments. | Polosa R et al. | — | 2011 | → |
| Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial. | Thompson N et al. | — | 2011 | → |
| Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006-2008 International Tobacco Control (ITC) Four Country Survey. | Fix BV et al. | — | 2011 | → |
| Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. | Wouda JA et al. | — | 2011 | → |
| Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration. | George O et al. | — | 2011 | → |
| Varenicline effects on craving, cue reactivity, and smoking reward. | Brandon TH et al. | — | 2011 | → |
| Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease. | Antoniu SA et al. | — | 2011 | → |
| Varenicline for tobacco dependence: panacea or plight? | Williams JM et al. | — | 2011 | → |
| What justifies a placebo-controlled trial of Varenicline for smoking cessation in patients with COPD? | Kotz D et al. | — | 2011 | → |
| α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. | Quik M et al. | — | 2011 | → |
| A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline. | Johnson TS | — | 2010 | → |
| A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients. | Dunn KE et al. | — | 2010 | → |
| Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. | Hendrickson LM et al. | — | 2010 | → |
| Addition of bupropion SR to varenicline alleviated depression and suicidal ideation: a case report. | Karam-Hage M et al. | — | 2010 | → |
| Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. | Hays JT et al. | — | 2010 | → |
| Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. | Hays JT et al. | — | 2010 | → |
| An investigation of bupropion substitution for the interoceptive stimulus effects of nicotine. | Wilkinson JL et al. | — | 2010 | → |
| An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. | Wilcox CS et al. | — | 2010 | → |
| A pilot study combining individual-based smoking cessation counseling, pharmacotherapy, and dental hygiene intervention. | Gonseth S et al. | — | 2010 | → |
| A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. | Faessel HM et al. | — | 2010 | → |
| A thoracic surgeon-directed tobacco cessation intervention. | Kozower BD et al. | — | 2010 | → |
| A tobacco reconceptualization in psychiatry: toward the development of tobacco-free psychiatric facilities. | Moss TG et al. | — | 2010 | → |
| Behavioral counseling and varenicline treatment for smoking cessation. | Swan GE et al. | — | 2010 | → |
| Clinical experience of varenicline for smoking cessation. | Jung JW et al. | — | 2010 | → |
| Cluster randomized trial in smoking cessation with intensive advice in diabetic patients in primary care. ITADI Study. | Roig L et al. | — | 2010 | → |
| Combination pharmacotherapy for stopping smoking: what advantages does it offer? | Ebbert JO et al. | — | 2010 | → |
| Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. | Linden K et al. | — | 2010 | → |
| Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. | Vemer P et al. | — | 2010 | → |
| Cross-validation of a new procedure for early screening of smoking cessation medications in humans. | Perkins KA et al. | — | 2010 | → |
| Current treatment options in smoking cessation. | Crain D et al. | — | 2010 | → |
| Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system? | Chaitman BR et al. | — | 2010 | → |
| Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review. | Hughes JR et al. | — | 2010 | → |
| Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. | Schnoll RA et al. | — | 2010 | → |
| Effects of bupropion on simulated demand for cigarettes and the subjective effects of smoking. | Madden GJ et al. | — | 2010 | → |
| Effects of continued tobacco use during treatment of lung cancer. | Waller LL et al. | — | 2010 | → |
| Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice. | Damaj MI et al. | — | 2010 | → |
| Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. | Rezvani AH et al. | — | 2010 | → |
| Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. | Johnson HM et al. | — | 2010 | → |
| Effects of smoking intensity and cessation on inflammatory markers in a large cohort of active smokers. | Asthana A et al. | — | 2010 | → |
| Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. | Rigotti NA et al. | — | 2010 | → |
| Evaluation of varenicline as an aid to smoking cessation in UK general practice - a THIN database study. | Blak BT et al. | — | 2010 | → |
| Evidence base and strategies for successful smoking cessation. | Black JH | — | 2010 | → |
| Gabapentin for smoking cessation. | Sood A et al. | — | 2010 | → |
| Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo. | Gonzales D et al. | — | 2010 | → |
| Influence of smoking abstinence and nicotine replacement therapy on heart rate and QT time-series. | Lewis MJ et al. | — | 2010 | → |
| Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial. | Toll BA et al. | — | 2010 | → |
| Mouse model predicts effects of smoking and varenicline on event-related potentials in humans. | Rudnick ND et al. | — | 2010 | → |
| Neural substrates of psychostimulant withdrawal-induced anhedonia. | D'Souza MS et al. | — | 2010 | → |
| Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. | Chatterjee S et al. | — | 2010 | → |
| Nicotine patch plus lozenge gives greatest increases in abstinence from smoking rates at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined. | Gonzales D | — | 2010 | → |
| Nicotine patch vs. nicotine lozenge for smoking cessation: an effectiveness trial coordinated by the Community Clinical Oncology Program. | Schnoll RA et al. | — | 2010 | → |
| Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. | Philip NS et al. | — | 2010 | → |
| Nicotinic receptors and stages of nicotine dependence. | Brennan KA et al. | — | 2010 | → |
| Novel α3β4 nicotinic acetylcholine receptor-selective ligands. Discovery, structure-activity studies, and pharmacological evaluation. | Zaveri N et al. | — | 2010 | → |
| Participation in a population-based physical activity programme as an aid for smoking cessation: a randomised trial. | Bize R et al. | — | 2010 | → |
| Phantasmidine: an epibatidine congener from the ecuadorian poison frog Epipedobates anthonyi. | Fitch RW et al. | — | 2010 | → |
| Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation. | Keating GM et al. | — | 2010 | → |
| Pharmacogenetics of smoking cessation therapy. | Kortmann GL et al. | — | 2010 | → |
| Pharmacokinetics of cytisine after single intravenous and oral administration in rabbits. | Astroug H et al. | — | 2010 | → |
| [Pharmacological profile and clinical findings on varenicline tartrate (Champix tablets)]. | Hizue M et al. | — | 2010 | → |
| Practical implications of ACC/AHA 2007 guidelines for the management of unstable angina/non-ST elevation myocardial infarction. | Patel PD et al. | — | 2010 | → |
| Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk Patients. | Xi ZX | — | 2010 | → |
| Predictors of post-treatment relapse to smoking in successful quitters: pooled data from two phase III varenicline trials. | Heffner JL et al. | — | 2010 | → |
| Primary care of the renal transplant patient. | Gupta G et al. | — | 2010 | → |
| Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. | Tonstad S et al. | — | 2010 | → |
| Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation. | Ravva P et al. | — | 2010 | → |
| Randomized trial: Quitline specialist training in gain-framed vs standard-care messages for smoking cessation. | Toll BA et al. | — | 2010 | → |
| Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. | Levin ED et al. | — | 2010 | → |
| Secondary prevention strategies for coronary heart disease. | Weiner SD et al. | — | 2010 | → |
| Secondary stroke prevention. | Spence JD | — | 2010 | → |
| Smoking cessation: an integral part of lung cancer treatment. | Cataldo JK et al. | — | 2010 | → |
| Smoking cessation intervention: an evidence-based approach. | Laniado-Laborín R | — | 2010 | → |
| Smoking cessation: the potential role of risk assessment tools as motivational triggers. | Young RP et al. | — | 2010 | → |
| Smoking outcome by psychiatric history after behavioral and varenicline treatment. | McClure JB et al. | — | 2010 | → |
| Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. | Fagerström K et al. | — | 2010 | → |
| The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. | O'Connor EC et al. | — | 2010 | → |
| The cardiologist and smoking cessation. | Aboyans V et al. | — | 2010 | → |
| The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. | Knight C et al. | — | 2010 | → |
| The efficacy of smoking cessation therapies in cardiac patients: a meta-analysis of randomized controlled trials. | Eisenberg MJ et al. | — | 2010 | → |
| Therapeutic advances in the treatment of nicotine addiction: present and future. | Casella G et al. | — | 2010 | → |
| The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. | Poling J et al. | — | 2010 | → |
| The Treatment of Obesity and Its Co-occurrence with Substance Use Disorders. | Vanbuskirk KA et al. | — | 2010 | → |
| [Tolerability profile of varenicline in current medical practice]. | Dupont P et al. | — | 2010 | → |
| Use of a liquid nicotine delivery product to promote smoking cessation. | Geimer N et al. | — | 2010 | → |
| Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. | Keating GM et al. | — | 2010 | → |
| Varenicline does not increase serum BDNF levels in patients with nicotine dependence. | Umene-Nakano W et al. | — | 2010 | → |
| Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. | Ebbert JO et al. | — | 2010 | → |
| Varenicline for smoking cessation in patients with coronary heart disease. | Ockene I et al. | — | 2010 | → |
| Varenicline in smoking cessation. | Tonstad S et al. | — | 2010 | → |
| Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence. | Perkins KA et al. | — | 2010 | → |
| Varenicline treatment decreases DNMT1 mRNA expression in lymphocytes of schizophrenic patients who are cigarette smokers. | Smith RC et al. | — | 2010 | → |
| Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries. | Fagerström K et al. | — | 2010 | → |
| Varenicline use in patients with mental illness: an update of the evidence. | Purvis TL et al. | — | 2010 | → |
| Abuse liability assessment of tobacco products including potential reduced exposure products. | Carter LP et al. | — | 2009 | → |
| Acute hepatic injury associated with varenicline in a patient with underlying liver disease. | Franck AJ et al. | — | 2009 | → |
| Alcoholism: a systems approach from molecular physiology to addictive behavior. | Spanagel R | — | 2009 | → |
| An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. | Bader P et al. | — | 2009 | → |
| A preliminary benefit-risk assessment of varenicline in smoking cessation. | Cahill K et al. | — | 2009 | → |
| A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. | Rigotti NA et al. | — | 2009 | → |
| A retrospective poison center review of varenicline-exposed patients. | Kreshak AA et al. | — | 2009 | → |
| Behavioral interventions in tobacco dependence. | Leone FT et al. | — | 2009 | → |
| Behavioral intervention to promote smoking cessation and prevent weight gain: a systematic review and meta-analysis. | Spring B et al. | — | 2009 | → |
| Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights. | Paterson NE | — | 2009 | → |
| Budgetary impact of varenicline in smoking cessation in the United Kingdom. | Taylor DC et al. | — | 2009 | → |
| Can smokers switch from a hospital-based to a community-based stop smoking service? an open-label, randomized trial comparing three referral schemes. | Lewis KE et al. | — | 2009 | → |
| Chronic obstructive pulmonary disease: an update on diagnosis and management issues in older adults. | Nazir SA et al. | — | 2009 | → |
| Clinical utility of varenicline for smokers with medical and psychiatric comorbidity. | Ebbert JO et al. | — | 2009 | → |
| Combination treatment with varenicline and nicotine replacement therapy. | Ebbert JO et al. | — | 2009 | → |
| Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. | Gariti P et al. | — | 2009 | → |
| Cost-effectiveness of varenicline for smoking cessation. | Keiding H | — | 2009 | → |
| Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. | Annemans L et al. | — | 2009 | → |
| Developing human laboratory models of smoking lapse behavior for medication screening. | McKee SA | — | 2009 | → |
| Development of pharmacotherapies for drug addiction: a Rosetta stone approach. | Koob GF et al. | — | 2009 | → |
| Differential contribution of genetic variation in multiple brain nicotinic cholinergic receptors to nicotine dependence: recent progress and emerging open questions. | Greenbaum L et al. | — | 2009 | → |
| Effect of varying levels of disease management on smoking cessation: a randomized trial. | Ellerbeck EF et al. | — | 2009 | → |
| Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence. | Ray R et al. | — | 2009 | → |
| Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice. | Biala G et al. | — | 2009 | → |
| Effects of nicotine in experimental animals and humans: an update on addictive properties. | Le Foll B et al. | — | 2009 | → |
| Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. | LeSage MG et al. | — | 2009 | → |
| Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. | Mills EJ et al. | — | 2009 | → |
| Emerging drugs for the treatment of tobacco dependence. | Ebbert JO | — | 2009 | → |
| Ethical concerns about non-active conditions in smoking cessation trials and methods to decrease such concerns. | Hughes JR | — | 2009 | → |
| Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea. | Bae JY et al. | — | 2009 | → |
| Factors associated with the use of aids to cessation in English smokers. | Kotz D et al. | — | 2009 | → |
| From the American Academy of Pediatrics: Technical report--Secondhand and prenatal tobacco smoke exposure. | Best D et al. | — | 2009 | → |
| Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. | Moreno AY et al. | — | 2009 | → |
| Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. | Halperin AC et al. | — | 2009 | → |
| Interventions for preventing weight gain after smoking cessation. | Parsons AC et al. | — | 2009 | → |
| Magnetic resonance imaging studies of cigarette smoking. | Azizian A et al. | — | 2009 | → |
| Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm. | Gordon E et al. | — | 2009 | → |
| Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. | McClure JB et al. | — | 2009 | → |
| Moving forward in smoking cessation: issues for psychiatric nurses. | Schroeder SA | — | 2009 | → |
| Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats. | Liu X et al. | — | 2009 | → |
| Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. | Schnoll RA et al. | — | 2009 | → |
| Nicotinic acetylcholine receptors: an overview on drug discovery. | D'hoedt D et al. | — | 2009 | → |
| Office management of COPD in primary care: a 2009 clinical update. | Belfer MH | — | 2009 | → |
| Peripheral arterial disease: considerations in risks, diagnosis, and treatment. | Mukherjee D et al. | — | 2009 | → |
| Pharmacotherapy for tobacco dependence. | Fant RV et al. | — | 2009 | → |
| Pharmacotherapy of addictive disorders. | Ross S et al. | — | 2009 | → |
| Population pharmacokinetic analysis of varenicline in adult smokers. | Ravva P et al. | — | 2009 | → |
| Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment. | Rose JE et al. | — | 2009 | → |
| Quitting smoking without a psychotic break: the potential link between nicotinic acetylcholine receptor partial agonists and neuropsychiatric adverse events. | O'Malley P | — | 2009 | → |
| Real world study to evaluate the effectiveness of varenicline and cognitive-behavioural interventions for smoking cessation. | Ramon JM et al. | — | 2009 | → |
| Removing obstacles in neuroscience drug discovery: the future path for animal models. | Markou A et al. | — | 2009 | → |
| Review: the need for smoking cessation among HIV-positive smokers. | Nahvi S et al. | — | 2009 | → |
| Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. | Purvis TL et al. | — | 2009 | → |
| Sibutramine for weight gain attenuation during smoking cessation with varenicline: a pilot study. | Sood A et al. | — | 2009 | → |
| Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century. | Laniado-Laborín R | — | 2009 | → |
| Smoking and depression: Is smoking cessation effective? | Ischaki E et al. | — | 2009 | → |
| Smoking cessation: an economic analysis and review of varenicline. | Faulkner MA | — | 2009 | → |
| Smoking cessation: How compelling is the evidence? A review. | Tønnesen P | — | 2009 | → |
| Smoking cessation in chronic obstructive pulmonary disease. | Tashkin DP et al. | — | 2009 | → |
| Smoking cessation: it is never too late. | Nilsson PM et al. | — | 2009 | → |
| Smoking cessation pharmacotherapy. | Frishman WH | — | 2009 | → |
| Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. | Bolin K et al. | — | 2009 | → |
| Smoking cessation through the utilization of pharmacotherapy. | Harrington KF et al. | — | 2009 | → |
| Subjective, cognitive/psychomotor, and physiological effects of aripiprazole in Chinese light and heavy smokers. | Liu Y et al. | — | 2009 | → |
| The effect of smoking prevalence at worksites on individual cessation behavior. | Nishiura C et al. | — | 2009 | → |
| The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. | Franklin TR et al. | — | 2009 | → |
| The neuropharmacological substrates of nicotine reward: reinforcing versus reinforcement-enhancing effects of nicotine. | Paterson NE | — | 2009 | → |
| The relevance and treatment of cue-induced cravings in tobacco dependence. | Ferguson SG et al. | — | 2009 | → |
| Tobacco control and nicotine addiction in Canada: current trends, management and challenges. | McIvor A | — | 2009 | → |
| Treating tobacco dependence in a medical setting. | Hurt RD et al. | — | 2009 | → |
| Treating tobacco dependence in light of the 2008 US Department of Health and Human Services clinical practice guideline. | Hays JT et al. | — | 2009 | → |
| Treatment of tobacco dependence in mental health and addictive disorders. | Hitsman B et al. | — | 2009 | → |
| Treatment strategies for peripheral artery disease. | McCann AB et al. | — | 2009 | → |
| Update in new medications for primary care. | Smetana GW et al. | — | 2009 | → |
| Update on peripheral arterial disease and claudication rehabilitation. | Salameh MJ et al. | — | 2009 | → |
| Update on smoking cessation therapies. | Glynn DA et al. | — | 2009 | → |
| Varenicline: a first-line treatment option for smoking cessation. | Garrison GD et al. | — | 2009 | → |
| Varenicline and bupropion sustained-release combination therapy for smoking cessation. | Ebbert JO et al. | — | 2009 | → |
| Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. | Gunnell D et al. | — | 2009 | → |
| Varenicline: a novel pharmacotherapy for smoking cessation. | Jiménez-Ruiz C et al. | — | 2009 | → |
| Varenicline augmentation in depressed smokers: an 8-week, open-label study. | Philip NS et al. | — | 2009 | → |
| Varenicline for smoking cessation: a placebo-controlled, randomized study. | Wang C et al. | — | 2009 | → |
| Varenicline for smoking cessation: A review of the literature. | Kaur K et al. | — | 2009 | → |
| Varenicline improves mood and cognition during smoking abstinence. | Patterson F et al. | — | 2009 | → |
| [Varenicline - pharmacological therapy of tobacco dependence]. | Tschabitscher P et al. | — | 2009 | → |
| Varenicline reduces alcohol self-administration in heavy-drinking smokers. | McKee SA et al. | — | 2009 | → |
| Visual hallucinations associated with varenicline: a case report. | Raidoo BM et al. | — | 2009 | → |
| Why won't our patients stop smoking? The power of nicotine addiction. | Mannino DM | — | 2009 | → |
| Worsening psychosis induced by varenicline in a hospitalized psychiatric patient. | DiPaula BA et al. | — | 2009 | → |
| A longer course of varenicline therapy improves smoking cessation rates. | Lee JH et al. | — | 2008 | → |
| Anti-nicotine abuse vaccines in the pipeline: an update. | Cerny EH et al. | — | 2008 | → |
| An update on therapeutics for tobacco dependence. | Lancaster T et al. | — | 2008 | → |
| A placebo-controlled trial of modafinil for nicotine dependence. | Schnoll RA et al. | — | 2008 | → |
| A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation. | Zernig G et al. | — | 2008 | → |
| A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations. | Robles GI et al. | — | 2008 | → |
| A vaccine against nicotine for smoking cessation: a randomized controlled trial. | Cornuz J et al. | — | 2008 | → |
| Beta2 subunit containing acetylcholine receptors mediate nicotine withdrawal deficits in the acquisition of contextual fear conditioning. | Portugal GS et al. | — | 2008 | → |
| Chronic obstructive pulmonary disease: an overview. | Devine JF | — | 2008 | → |
| Cigarette smoking and diffuse lung disease. | Patel RR et al. | — | 2008 | → |
| Clinical management of chronic obstructive pulmonary disease and asthma in an obese patient. | Lessard A et al. | — | 2008 | → |
| Comparison of expired carbon monoxide and plasma cotinine as markers of cigarette abstinence. | Jatlow P et al. | — | 2008 | → |
| Correlates of smoking cessation in a nationally representative sample of U.S. adults. | Agrawal A et al. | — | 2008 | → |
| Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. | Hoogendoorn M et al. | — | 2008 | → |
| Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. | Howard P et al. | — | 2008 | → |
| Cytisine for smoking cessation: a research agenda. | Etter JF et al. | — | 2008 | → |
| Decreased brain reward function during nicotine withdrawal in C57BL6 mice: evidence from intracranial self-stimulation (ICSS) studies. | Johnson PM et al. | — | 2008 | → |
| Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. | Jackson KJ et al. | — | 2008 | → |
| Diffuse exanthema in a patient receiving varenicline. | Song W et al. | — | 2008 | → |
| Disrupting nicotine reinforcement: from cigarette to brain. | Rose JE | — | 2008 | → |
| Drugs (including oxygen) in severe COPD. | Albert P et al. | — | 2008 | → |
| Early vascular aging (EVA): consequences and prevention. | Nilsson PM | — | 2008 | → |
| Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. | Feng B et al. | — | 2008 | → |
| Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. | West R et al. | — | 2008 | → |
| Efficacy and safety of varenicline for smoking cessation. | Hays JT et al. | — | 2008 | → |
| Evidence-based practice to assist women in hospital settings to quit smoking and reduce cardiovascular disease risk. | Buchanan L et al. | — | 2008 | → |
| Fifty years of Biochemical Pharmacology: the discipline and the journal. | Enna SJ et al. | — | 2008 | → |
| Genetics of nicotine dependence and pharmacotherapy. | Lessov-Schlaggar CN et al. | — | 2008 | → |
| Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers. | McColl SL et al. | — | 2008 | → |
| Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease. | Bullen C | — | 2008 | → |
| Individual differences in adoption of treatment for smoking cessation: demographic and smoking history characteristics. | Shiffman S et al. | — | 2008 | → |
| Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal. | De Biasi M et al. | — | 2008 | → |
| It's about time--directing our attention toward modifying the course of COPD. | Cazzola M et al. | — | 2008 | → |
| Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers. | Faessel HM et al. | — | 2008 | → |
| Management of anxiety and depression in patients with COPD. | Yohannes AM | — | 2008 | → |
| Management of cardiovascular disease in renal transplant recipients. | Shirali AC et al. | — | 2008 | → |
| Metabotropic glutamate 5 receptor (mGluR5) antagonists decrease nicotine seeking, but do not affect the reinforcement enhancing effects of nicotine. | Palmatier MI et al. | — | 2008 | → |
| Multidisciplinary care of the patient with chronic obstructive pulmonary disease. | Kuzma AM et al. | — | 2008 | → |
| Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines. | Reus VI et al. | — | 2008 | → |
| Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. | Pirmoradi P et al. | — | 2008 | → |
| New insights in preventive cardiology and cardiac rehabilitation. | Franklin BA et al. | — | 2008 | → |
| Nicotine patch therapy prior to quitting smoking: a meta-analysis. | Shiffman S et al. | — | 2008 | → |
| Nicotine receptor partial agonists for smoking cessation. | Cahill K et al. | — | 2008 | → |
| Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. | George TP et al. | — | 2008 | → |
| Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. | Tutka P | — | 2008 | → |
| Partial nicotinic acetylcholine (alpha4beta2) agonists as promising new medications for smoking cessation. | Singh J et al. | — | 2008 | → |
| Pharmacologic risk factor management in peripheral arterial disease: a vade mecum for vascular surgeons. | Rehring TF et al. | — | 2008 | → |
| Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. | Eisenberg MJ et al. | — | 2008 | → |
| Pharmacotherapy for smoking cessation. | Carrozzi L et al. | — | 2008 | → |
| Polyethylene glycol-based homologated ligands for nicotinic acetylcholine receptors. | Scates BA et al. | — | 2008 | → |
| Positive modulation of GABA(B) receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. | Paterson NE et al. | — | 2008 | → |
| Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. | Tietje KR et al. | — | 2008 | → |
| Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. | Anthenelli RM et al. | — | 2008 | → |
| Prevention strategies for cardiovascular disease in HIV-infected patients. | Stein JH et al. | — | 2008 | → |
| Primary care of the patient with chronic obstructive pulmonary disease-part 1: frontline prevention and early diagnosis. | Radin A et al. | — | 2008 | → |
| Review. Evidence-based treatments of addiction. | O'Brien CP | — | 2008 | → |
| Smoking: a deadly pleasant habit--is there a way out? | Richter D | — | 2008 | → |
| Smoking after cardiac transplantation. | Botha P et al. | — | 2008 | → |
| Smoking and suicide: a brief overview. | Hughes JR | — | 2008 | → |
| Smoking cessation and lung cancer: oncology nurses can make a difference. | Cooley ME et al. | — | 2008 | → |
| Smoking cessation in pregnancy: why, how, and what next... | Crawford JT et al. | — | 2008 | → |
| Smoking cessation readiness: are your patients ready to quit? | Woody D et al. | — | 2008 | → |
| Smoking cessation: significance and implications for children. | Borchers AT et al. | — | 2008 | → |
| Smoking cessation therapy with varenicline. | Mohanasundaram UM et al. | — | 2008 | → |
| Smoking cessation treatment in community-based substance abuse rehabilitation programs. | Reid MS et al. | — | 2008 | → |
| Smoking, health and ageing. | Nicita-Mauro V et al. | — | 2008 | → |
| Strategies for smoking cessation: what is new and what works? | Cummings KM et al. | — | 2008 | → |
| Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice. | Fowler CD et al. | — | 2008 | → |
| The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. | Niaura R et al. | — | 2008 | → |
| The Impact of CAROtid plaque Screening on Smoking (CAROSS) cessation and control of other cardiovascular risk factors: Rationale and design of a randomized controlled trial. | Rodondi N et al. | — | 2008 | → |
| The Pharmacist's Role in Smoking Cessation. | Wick JY | — | 2008 | → |
| The principles of agonist pharmacotherapy for psychostimulant dependence. | Shearer J | — | 2008 | → |
| The use of bupropion SR in cigarette smoking cessation. | Wilkes S | — | 2008 | → |
| Tobacco addiction. | Hatsukami DK et al. | — | 2008 | → |
| Tobacco and aboriginal people in NSW. | Ivers RG | — | 2008 | → |
| Tobacco smoking cessation management: integrating varenicline in current practice. | Galanti LM | — | 2008 | → |
| Treatment of tobacco dependence. | Burke MV et al. | — | 2008 | → |
| Update on pharmacologic and nonpharmacologic therapies for smoking cessation. | Schmelzle J et al. | — | 2008 | → |
| Update on pharmacologic options for smoking cessation treatment. | Nides M | — | 2008 | → |
| Update on smoking cessation interventions for the primary care physician. Introduction. | Rennard SI | — | 2008 | → |
| Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. | Raybuck JD et al. | — | 2008 | → |
| Varenicline and its role in smoking cessation. | Kapoor S | — | 2008 | → |
| Varenicline and smokers with mental illnesses. | Lasser KE et al. | — | 2008 | → |
| Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003. | Bolin K et al. | — | 2008 | → |
| Varenicline for smoking cessation. | BMJ Group | — | 2008 | → |
| Varenicline for tobacco dependence. | Hays JT et al. | — | 2008 | → |
| Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. | Pumariega AJ et al. | — | 2008 | → |
| Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. | Stapleton JA et al. | — | 2008 | → |
| Varenicline in the treatment of tobacco dependence. | Fagerström K et al. | — | 2008 | → |
| Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. | Aubin HJ et al. | — | 2008 | → |
| ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. | Anderson JL et al. | — | 2007 | → |
| ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. | Anderson JL et al. | — | 2007 | → |
| A double-blind study evaluating the long-term safety of varenicline for smoking cessation. | Williams KE et al. | — | 2007 | → |
| Advances in the management of chronic obstructive pulmonary disease. | Meinke L et al. | — | 2007 | → |
| Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review. | Leeman RF et al. | — | 2007 | → |
| Antidepressants for smoking cessation. | Hughes JR et al. | — | 2007 | → |
| A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. | Glover ED et al. | — | 2007 | → |
| A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. | Tsai ST et al. | — | 2007 | → |
| A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. | Covey LS et al. | — | 2007 | → |
| A research agenda for assessing the potential contribution of genomic medicine to tobacco control. | Hall WD | — | 2007 | → |
| Aspects on pathophysiological mechanisms in COPD. | Larsson K | — | 2007 | → |
| Bibliography. Current world literature. Obstetric and gynecological anaesthesia. | — | — | 2007 | → |
| Breaking the ties of nicotine dependence. | Bennett SM et al. | — | 2007 | → |
| Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors. | Tapia L et al. | — | 2007 | → |
| Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. | O'Donnell DE et al. | — | 2007 | → |
| Certification in tobacco treatment: why should home care nurses bother? | O'Brien M | — | 2007 | → |
| Chemical medicine: novel 10-substituted cytisine derivatives with increased selectivity for alpha4beta2 nicotinic acetylcholine receptors. | Kozikowski AP et al. | — | 2007 | → |
| Chronic obstructive pulmonary disease in the older patient. | Nazir SA et al. | — | 2007 | → |
| Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. | Ochoa EL et al. | — | 2007 | → |
| Comment: Oral varenicline for smoking cessation. | Gonzales D et al. | — | 2007 | → |
| Community-acquired pneumonia: what is relevant and what is not? | Talwar A et al. | — | 2007 | → |
| Depression and smoking cessation: does the evidence support psychiatric practice? | Lembke A et al. | — | 2007 | → |
| Dopamine D3 receptor ligands for the treatment of tobacco dependence. | Le Foll B et al. | — | 2007 | → |
| Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers. | Reid MS et al. | — | 2007 | → |
| Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. | Nakamura M et al. | — | 2007 | → |
| Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. | Fletcher GF et al. | — | 2007 | → |
| Emerging issues in smoking among adolescent and adult cancer survivors: a comprehensive review. | Klosky JL et al. | — | 2007 | → |
| Explaining the escalation of drug use in substance dependence: models and appropriate animal laboratory tests. | Zernig G et al. | — | 2007 | → |
| Genetics and smoking cessation improving outcomes in smokers at risk. | Lerman CE et al. | — | 2007 | → |
| Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. | Rabe KF et al. | — | 2007 | → |
| Interference with smoking-cessation effects of varenicline after administration of immediate-release amphetamine-dextroamphetamine. | Whitley HP et al. | — | 2007 | → |
| Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). | Gray J et al. | — | 2007 | → |
| Maximizing smoking cessation in clinical practice: pharmacologic and behavioral interventions. | Nides M et al. | — | 2007 | → |
| Multivariate framework of the Brief Questionnaire of Smoking Urges. | Cappelleri JC et al. | — | 2007 | → |
| Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. | Arneric SP et al. | — | 2007 | → |
| Nicotine interventions with comorbid populations. | Hall SM | — | 2007 | → |
| Nicotine receptor partial agonists for smoking cessation. | Cahill K et al. | — | 2007 | → |
| Oral varenicline for smoking cessation. | Zierler-Brown SL et al. | — | 2007 | → |
| Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. | Rollema H et al. | — | 2007 | → |
| Pharmacotherapy for tobacco cessation: nicotine agonists, antagonists, and partial agonists. | Karam-Hage M et al. | — | 2007 | → |
| Preventing chronic obstructive pulmonary disease: what is known and what needs to be done to make a difference to the patient? | Wise RA et al. | — | 2007 | → |
| Quitlines a tool for research and dissemination of evidence-based cessation practices. | McAfee TA | — | 2007 | → |
| Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. | Rollema H et al. | — | 2007 | → |
| Recommendations for the use of pharmacological smoking cessation strategies in pregnant women. | Coleman T | — | 2007 | → |
| Rimonabant for treating tobacco dependence. | Steinberg MB et al. | — | 2007 | → |
| Smoking cessation: an overview of treatment options with a focus on varenicline. | Stack NM | — | 2007 | → |
| Smoking cessation for cardiac patients. | Dornelas EA et al. | — | 2007 | → |
| Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. | Tønnesen P et al. | — | 2007 | → |
| Smoking cessation interventions in clinical practice. | Cornuz J | — | 2007 | → |
| Smoking cessation: lessons learned from clinical trial evidence. | Reid RD et al. | — | 2007 | → |
| Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations. | Frishman WH | — | 2007 | → |
| Stroke prevention in the high-risk patient. | Spence JD | — | 2007 | → |
| The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline. | Hollis JF et al. | — | 2007 | → |
| The efficacy of the combination of sertraline with buspirone for smoking cessation. A randomized clinical trial in nondepressed smokers. | Carrão JL et al. | — | 2007 | → |
| Therapeutic options and challenges for substances of abuse. | Gardner TJ et al. | — | 2007 | → |
| Therapy insight: peripheral arterial disease and diabetes--from pathogenesis to treatment guidelines. | Mohler ER | — | 2007 | → |
| The year in atherothrombosis. | Sanz J et al. | — | 2007 | → |
| Tobacco control for anesthesiologists. | Warner DO | — | 2007 | → |
| Tobacco dependence in surgical patients. | Warner DO | — | 2007 | → |
| Treating tobacco dependence in women. | Schnoll RA et al. | — | 2007 | → |
| Treating tobacco dependence: review of the best and latest treatment options. | Ebbert JO et al. | — | 2007 | → |
| Update in addiction medicine for the generalist. | Gordon AJ et al. | — | 2007 | → |
| Update in chronic obstructive pulmonary disease 2006. | Rabe KF et al. | — | 2007 | → |
| Update in lung cancer 2006. | Dubey S et al. | — | 2007 | → |
| Update on the pharmacologic therapy for chronic obstructive pulmonary disease. | Hanania NA et al. | — | 2007 | → |
| Vaccination against nicotine: an emerging therapy for tobacco dependence. | Maurer P et al. | — | 2007 | → |
| Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. | Steensland P et al. | — | 2007 | → |
| Varenicline: A review of the literature and place in therapy. | Whitley HP et al. | — | 2007 | → |
| Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. | Lam S et al. | — | 2007 | → |
| Varenicline for smoking cessation. | Tonstad S | — | 2007 | → |
| Varenicline: progress in smoking cessation treatment. | Glover ED et al. | — | 2007 | → |
| Varenicline: the newest agent for smoking cessation. | Potts LA et al. | — | 2007 | → |
| What have we learned from large drug treatment trials in COPD? | Calverley PM et al. | — | 2007 | → |
| Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline? | Doggrell SA | — | 2007 | → |
| Current and emerging pharmacotherapies for treating tobacco dependence. | Schnoll RA et al. | — | 2006 | → |
| Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. | Wu P et al. | — | 2006 | → |
| Partial agonism at nicotinic receptors with varenicline--a new approach to smoking cessation. | Doggrell SA | — | 2006 | → |
| Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. | Dwoskin LP et al. | — | 2006 | → |
| Varenicline: a review of its use as an aid to smoking cessation therapy. | Keating GM et al. | — | 2006 | → |